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CHAPTER 
Introduction 

Introduction 
REUTZFELDT-JAKOB DISEASE (CJO) is a rare neurodegene-
rative disorder with a highly interesting aetiology and 
potentially important public health implications. l In 
aetiological terms, CJD is one of the human prion diseases, 
characterised by rapid neurodegeneration leading to a 
characteristic spongiform encephalopathy.' From a publlc health 
perspective, CJO is of interest because of the possible link 
between the bovine spongifonl1 encephalopathy (BSE) and CJO.3 
In this thesis studies on the incidence, risk factors and prognosis 
of CJO are reported. It is based on a collaborative European study 
In which the incidence of CJO was investigated in various Euro-
pean countries on the basis of national registries. In addition a 
collaborative case-control study of determinants of CJO was per-
formed in the European countries with a CJO register. And finally, 
the sUlvival of CJO patients was estimated on the basis of patients 
in the registers. 
Ule outline of this thesis is as follows. Chapter 2 presents a re-
analysis of former case-control studies on determinants of CJO 
conducted in the seventies and early eighties in the US, UK and 
Japan. In chapter 3 the methods of the various studies are de-
scribed. In particular, details on the build-up of the register for 
CJO in the Netherlands and Belgium are given, with particular 
emphasis on the ascertainment of patients. Chapter 3 also de-
scribes the methodology of the case-control study that was con-
ducted In various European countries to investigate risk factors for 
CJO. Chapter 4 presents the incidence of CJO in Europe from 1993 
to 1995 based on registers in Belgium, France, Germany, Italy, the 
Netherlands, Slovakia, and the United Kingdom. In chapter 5 the 
risk factors for CJO are described, based on the collaborative case-
control study of CJD conducted in various European countries 
between 1993 and 1995. In chapter 6 the survival of CJO and 
prognostic factors for survival are described based on CJO patients 
in the European registers. In the last chapter the methodological 
aspects of the studies of incidence, risk factors and prognosis are 
discussed, and the implications of the findings and suggestions for 
future research are presented. 
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Review 
Abstract 
To review the evidence for risk factors of Creutzfeldt-Jakob disea-
se (CJD), we pooled and re-analyzed the raw data of three case-
control studies. 'nle pooled data set comprised a total of 178 cases 
and 333 controls. 111e strength of association between CJD and 
putative risk factors was assessed by computing the odds ratio as 
estimate of the relative risk. 111e risk of CJD was statistically signi-
ficantly increased for subjects with a family histOlY of CJD (odds 
ratio~19.1;950/0 confidence intervall.1 - 348.0). FtlI1her, there was 
a significant association between the risk of CJD and a history of 
psychotic disease (odds ratio~9.9;950/0 confidence interval 1.1 -
86.0. Although not significantly increased, there was an elevated 
risk of CJD for subjects with a family histolY of dementia, a history 
of poliomyelitis, subjects employed as health professionals and 
subjects ever exposed to cows and sheep. No association could be 
shown with organ meat consumption including brain. The nega-
tive results of this fe-analysis fe-emphasises the absence of a com-
mon risk factor in all CJD patients. However, the ongoing epi-
demiological surveillance of CJD in several European countries 
may provide more evidence to exclude any environmental expo-
sure early in childhood. 
Review 
Introduction 
Creutzfeldt-Jakob disease (CJD) Is a transmissible sponglform en-
cephalopathy that may occur in an inherited, infectious, or spora-
dic form. CJD may be caused by various mutations In the prion 
protein gene (PRNP) on chromosome 20. 1 However, these muta-
tions are found only in familial C]D patients, comprising not more 
than 15% of all CJD patients.' The infectious form of CJD appears 
to be rare2 and limited to iatrogenic transmission through neUfO-
surgelY and electro-encephalographic electrode implantation3..Q, 
corneal transplantation7 and human growths+ 1o and gonadotro-
phin ll hormone. For the large majority of patients with sporadic 
C]D, the cause remains unknown. Studies on risk factors for CJD 
have yielded controversial results and did not show evidence for a 
common risk factor. 12+ 17 An increased risk of CJD has been re-
ported for subjects with a history of infection12,J7, surgery of the 
head13,11, trauma to the head or bodyI3,11, tonometryH, consump-
tion of pork 15, and contact with various anfmais16,17 in some but 
not all studies. nle recent infection of British bovine cattle 
through protein supplements derived from animal carcasses has 
fueled speculations on the possibility of infection of humans 
through meat consumption and animal contact. Other than the 
established transmission of Kuru through cannibalistic rituals l ,2, 
findings of studies on (organ) meat consumption including brain 
have not yielded consistent results. !l,IS 
Some of the conflicting results may be explained by the small size 
of the individual studies yielding only limited statistical power to 
detect an association. To review the evidence for the risk factors 
previously reported, we pooled and re-analyzed the raw data of 
three case-control snldies of CJD. As no meta-analysis of the exist-
ing case-control studies on Creutzfeldt -Jakob disease has been 
performed, we present here our results. 
Patients and methods 
All formal case-control studies of CJD were ascertained through 
MEDLINE search and personal communications. nms, four studies 
7 
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were identified as eligible for the re_analysis,12-17 To increase the 
comparability between studies, we have restricted the analysis to 
the three studies comprising patients diagnosed with CJD accord-
ing to the criteria of Masters et al. 18 One sUldy was performed in 
]apan13, one in the United States of America 14,15,16 and one in the 
United Kingdom.17 11,e pooled data set comprised a total of 178 
cases (mean age at diagnosis 61 years; SD=9.5; range 26-81 years) 
and 333 controls. For each study, ascertainment of cases and con-
trols and data-collection will be discussed here briefly. 
Japan 
11,e study conducted in Japan comprised 60 cases. 13 According to 
the criteria of Masters et al,18 50% were classified as probable, 47% 
as definite and 3% as transmissible CJD. For this study, neurologi-
cal and psyd1iatric institutions throughout Japan were requested 
to report patients diagnosed with CJD in the period 1975-1977. 
Patients were compared to a total of 109 age-matched controls 
(+/- 5 years), including 50 spouses and 59 neighborhood controls. 
In some instances, public health personnel served as neighbor-
hood control. TIle response rate was 80% in cases, 78010 in spouses 
and 93% in neighborhood controls. Data were collected by a 
stnlcUlfed interview. FOf cases the data were obtained from the 
spouse. Control subjects were questioned directly. 
USA 
111e study performed in the United States comprised 26 cases of 
which 23% were classified as probable CJD, 46% as definite and 
31% as transmissible. I4,I5,16 Patients were ascertained through re-
cords submitted to the Laboratory of Central Nervous System 
Studies of the National Institutes of Health from Pennsylvania, 
New Jersey, Maryland, New York and Delaware. Patients were 
eliagnosed with C.JD in the period 1970-1981. Two control groups 
were selected: hospital controls diagnosed with a non-neurologi-
cal disease at the hospital where the patient was diagnosed (n=22; 
matching sex and age +/- 5 years) and relative controls (n=18; 
matching sex and age +/- 10 years). 11,e response rate was 96% in 
cases, 85% in hospital controls and 86% in relative controls. Data 
were collected by a structured Interview of the spouse (58"10), 
Review 
child (27%), sibling (11%) or parent (4%) of the case. Control 
subjects were questioned directly. 
UK 
11,e study conducted in the United Kingdom comprised 92 cases 
of whom 24% were classified as probable and 76% as definite 
C]D.17 Patients diagnosed with C]D in the period 1980-1984 were 
ascertained through neurological centers in England and Wales 
and through death certificates of the Office of Population, Census-
es and Surveys. For each case, two age- and sex-matched controls 
were derived from the hospital where the patient was diagnosed 
(n=184; matching age +/- 4 years). Of the two controls, one suf-
fered from a neurological disorder other than C]D, the other from 
a non-neurological disorder. The response rate was 75% for cases 
and is unknown for controls. For cases as well as controls the data 
were collected by interviewing an informant. '!he relationship to 
the informant was matched in 87% for cases and controls. In 78"'" 
of the subjects it was the spouse, in 16% a child and in 6% a sib-
ling. 
Analysis 
'!his re-analysls was based on the original raw data of the three 
studies. We only included risk factors assessed comparably in at 
least two out of three studies. 11,e risk factors studied were: 0) 
family hlstOlY of C]D, dementia and Parkinson's disease; (2) medi-
cal histOlY, including head trauma, hospitalization for psychotic 
disease, history of poliomyelitis, hepatitis, jaundice, allergy and 
blood transfusion; (3) employment as health professional; (4) ex-
posure to animals; (5) living in a nlfal areaj and (6) consumption 
of organ meat. Exposures of cases, relatives and spouses may be 
similar for family and occupational history,animal exposure, place 
of residence and diet, due to the shared environment. As this may 
bias the results towards the null hypothesis, relative and spouse 
controls were excluded in the analysis of these putative risk fac-
tors. l1ms, the number of subjects included in the study may vary 
according to the number of studies and control subjects included, 
as well as to the missing values within a study. For each risk fac-
9 
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tOf, we repOlt the number of subjects exposed and the total num-
ber of subjects for whom data on the risk factor were available. 
The strength of association between CJD and putative risk factors 
was assessed by computing the odds ratio (OR) as an estimate of 
the relative risk.19 Relative risks were estimated by maximum Hke-
lihood methods and the 950/0 confidence intelvals (95% Ci) were 
based on the asymptotic standard errors. Confounding by age, sex 
and study center was taken into account by including these vari-
ables into the logistic regression model. 
Family history of CJD, dementia and Parkinson's disease for cases 
and controls are reported in the table. A positive family histOlY of 
CJD was found only in CJD cases. A total of seven (4%) cases had 
a relative with CJD. An increased risk of CJD was also obselved 
for cases with a positive famHy history of dementia in any relative, 
which was borderline significant (OR ~1.9; 95% CI 0.9-4.1). When 
restricting the analysis to first degree relatives, the OR remained 
increased (OR~1.8; 95% CI 0.8-4.0 not in table). 
With regard to the medical histOlY (table), significantly more CJD 
patients than controls had a history of hospitalization for psychotic 
disease. Three of five CJD cases were hospitalized 15 years or 
more before the onset of CJD. No association was found with 
head trauma, hepatitis, jaundice, allergy or blood transfusion. ll1e 
risk of CJD associated with poliomyelitis was increased (OR 3.9; 
95% CI 0.3-43.4). However, the significance is difficult to interpret 
as the number of exposed subjects is very small. Fewer CJD pa-
tients than controls had a histOlY of surgery. 11,e difference was 
statistically significant for abdominal surgelY. 
A non-significantly increased risk of CJD was found for subjects 
exposed to patient tissue through their employment as a health 
professional, i.e., medical doctors, nurses, dentists, iaboratolY 
workers, ambuiance employees (OR 1.5; 95% CI 0.5-4.1) (table). 
Exposure to cows and sheep was associated with a borderline 
significant increased risk of CJD (OR 1.7; 95% CI 0.9-3.1 and OR 
1.6; 95% CI 0.9-2.9, respectively). Also, there was a non-signifi-
cantly increased risk of CJD for subjects who lived in a mral area 
Review 
Table - Family history of CJD, dementia and Parkinson's disease, medical 
history, and occupational, animal and dietary exposures and the risk of 
Creu!zfeldt·Jakob disease 
Family history 
CJDI3-17*§ 
Dementia 14-17* 
Parkinson's disease'4-17* 
Medical history 
Psychotic diseaseI3.17* 
Head traumaI3-17* 
Poliomyelitis 13-17* 
Hepatitis/jaundice 14--17* 
Allergyl3·17* 
Blood transfusion '3.17* 
SurgeI}': 
central nelVous system'3,17* 
eye '3-17* 
abdominaI13.17* 
tonsillectomy 13-17* 
Cas est Controlst 
71166 
15/126 
7/117 
5/111 
27/176 
2/168 
9/118 
39/174 
171174 
0/149 
6/176 
39/176 
13/171 
01285 
171212 
7/194 
1/219 
55/329 
11332 
181222 
64/330 
45/328 
to/301 
23/332 
96/331 
32/331 
Occupational, animal and dietary exposure 
Health professional
'
4-I7* 8/119 7/206 
Cowexposure'3-17* 
Sheep exposure 13.17* 
Organ meat: brain 13-17* 
Iiver'3.17* 
kidneyl3-17* 
Studies with data on risk factor 
26/95 26/145 
26/1 71 251262 
14/177 331261 
t04/ 11 7 179/206 
61/86 135/179 
Odds ratio 
[95% confidence intervall 
Crude Adjustedt 
18.8 11.0·341.21' 
1.610.7·3.21 
1.7 10.6·5.01 
10.311.2·89.81' 
0.9 10.6·1.51 
4.010.4·44.61 
0.9 10.4·2.21 
1.210.8·1.91 
0.7 10.4·1.21 
0.310.1·1.21 
0.510.2·1.11 
0.7 10.5·1. 11 
0.8 10.4·1.51 
1.5 10.6·4.21 
1.7 10.9·3.21 
1.6 10.9·2.91 
0.6 10.3·1.21 
1.210.6·2.51 
0.8 10.4·1.41 
19.1 11.1·348.01' 
1.9 10.9-4.11 
1.7 10.6·5.01 
9.911.1·86.11' 
0.9 10.5-1.51 
3.9 10.3·43.41 
0.9 10.4·2.11 
1.210.8·2.01 
0.610.4·1.21 
0.3 10.1·1.21 
0.510.2·1.11 
0.7 10.4·1.01' 
0.7 10.4·1.41 
1.5 10.5·4.11 
1.7 10.9·3.11 
1.610.9·2.91 
0.6 10.3·1.81 
1.3 10.6·2.61 
0.8 10.3·1.41 
Number of subjects with a positive hlstol}' or subjects exposed/total number of subjects in 
analysis 
t adjusted for age, sex and study site 
§ CJD: Creutzfeldt-Jakob disease 
~ p<0.05 
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at diagnosis (OR 1.4; 95% CI 0.8-2.4; not in table). Consumption of 
organ meat including braio, liver and kidney was not associated 
with an increased risk of CJD (table). 
Discussion 
12 
In this fe-analysis of case-control studies, the risk of CJD was sta-
tistically significantly increased for subjects with a family history of 
CJD. We also found a statistically significant association between 
the risk of CJD and the patient's history of psychotic disease. No 
statistically significant association could be shown for medical his-
tory other than psychosis or with organ meat consumption. Al-
though not significantly increased, more CJD patients than con-
trols had a family history of dementia, a history of poliomyelitis, 
an occupational history as health professional, history of exposure 
to cows and sheep, and had lived in a rural area. 
n,e internal validity of this re-analysis depends on the validity of 
the individual studies. Selection bias may have occurred through 
non-response in cases and controls in the individual studies. Fur-
ther, conu'ol selection differed considerably across studies. How-
ever, to distort the findings, non-response and control selection 
should be associated with the risk factors studied. 111is seems un-
likely for IllDst risk factors. However, in the case of Iuedical h1sto-
lY, risk factor exposure lllay have been associated with control 
selection in the largest study conducted in the UK,17 which was 
hospital based. n,e use of hospital controls may have led to high 
exposure frequencies for medical disorders, surgery, and blood 
transfusion. ll1is may explain the lower frequency of surgery in 
CJD patients compared to controls. Unfortunately, the a priori sta-
tistical power of an analysis limited to the two small studies from 
Japan13 and the US 11~I6 was too low to yield a meaningful solution 
to this problem. Another source of information bias might have 
been biased recall of putative risk factors. Also, the data collection 
through informants for cases and personal interviews for controls 
might have biased the data in two out of three studies. To take 
this bias into account, we restricted the analysis to exposures not 
easily forgotten by controls and informants. For this reason, family 
history of dementia was restricted to first degree relatives and the 
Review 
patient's history of psychotic disease to those requiring hospItali-
zation. Further, we checked whether the association with a risk 
factor was found consistently across studies. In each of the stud-
ies, a family histOlY of dementia, history of psychotic disease, 
employment as a health professional and exposure to cows and 
sheep was associated with an increased CJD risk. nlis suggests 
that if bias occurred, it must have occurred in all studies similarly 
despite the differences in the design among studies. 
Another issue is that the statistical power of our analysis may have 
been limited for rare exposures. Although we pooled the data of 
all case-control sntdies in which the cases met the criteria for CJD 
by Masters et al,18 the number of patients Included in this re-
analysis was stili smali which is reflected in the width of the 95% 
confidence intervals. Given an exposure frequency in controls of 
10%, a significance level of 5% (two-sided) and statistical power 
of 90%, the smaliest detectable relative risk In a study of 200 cases 
and 200 controls Is 2.5. 19 If the exposure frequency is only 1 %, the 
smallest detectable relative risk under these conditions is 8.0,19 
which is a strength of association seldom observed in epidemio-
logic research. 
Despite the limitations, our analysis showed a significant associa-
tion between history of psychotic disease and the risk of CJD. 
Whether psychotic disease is a risk factor for CJD or Is merely an 
early symptom of CJD pathology is undetermined. Future studies 
on the relationship between CJD and psychotic disease may be 
relevant. Our study shows familial aggregation of CJD, which may 
be explained by mutations in the prion protein (PRNP) gene that 
segregate in the families. l ,2o Also, hOlllOZygosity at codon 129 may 
be associated with an increased suscepUbiHty to prlon dis-
eases. 21 ,22 Our re-analysis showed a borderline significant asso-
ciation between CJD and family history of dementia. In a number 
of patients with familial forms of dementia, there have been PRNP 
lllutations23 and the familial aggregation of CJD and dementia may 
therefore be related to PRNP nlUtations segregating in these 
families. However, other genetic factors, e.g. the apolipoprotein E 
gene (associated with both the risk of CJD" and Alzheimer's 
disease25) or non-genetic factors, may underlie the relationship; 
13 
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studies of families in which CJD and dementia aggregate may be 
of interest. 
Our re-analysis did not support a number of previously reported 
associations. When pooling the data of the three studies, there 
was no association of the CJD risk with head trauma Of the con-
sumption of organ meat including brain. TIle latter was associated 
with an increased risk of CJD in the study of Bobowick12 , which is 
not included in the present fe-analysis. Based on our findings, 
blood transfusion did not increase the risk of CJD in the period 
studied. 111ere was no significant evidence in our study of trans-
mission of CJD among humans or frol11 cattle to human. However, 
there was a non-significant increase in risk of cJn for subjects 
employed as health professionals, subjects ever exposed to cows 
and sheep, and living in a filmi area. In Ollr fe-analysis the power 
to assess a statistically significant relationship for exposure to pa-
tients and exposure to animals was low. FtHther, the individual 
studies were performed in the seventies and early eighties, when 
information in particular on inherited prion diseases among hu-
mans and animals was not yet available, which has limited the 
possibility to separate genetic and non-genetic patients in the. pre-
sent fe-analysis. TIle negative results of our fe-analysis are impor-
tant in the light of public health to reassure the population that 
there are no common risk factors for Creutzfeldt-Jakob disease. 
OUf data cannot exclude an environmental source of infection that 
might have occurred early in childhood. TIle ongoing systematic 
epidemiological surveillance of CJD in several European countries 
might provide evidence of such exposure as residential histories 
throughout life are studied.26 TIlese studies with similar design 
will be highly comparable and will therefore be abie to resolve 
the problem of selection bias and of the limited statistical power 
of our re-analysis. 
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3.1 Introduction 
Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative disor-
der. Its infectious nature was demonstrated in 1968 through 
successful transmission to primates. l Since the outbreak of bovine 
spongiform encephalopathy (BSE) in cattle in the United Kingdom 
in 1986, the hypothetical risk of U'ansmission of the infectious 
agent to humans prompted the UK Mlnistly of Health to re-
institute the national prospective epidemiological surveillance of 
CJD.2 Also in other European countries concern was expressed 
about a possible link between animal sponglform encephalopathy 
(among others scrapie and BSE) and human spongiform 
encephalopathy including CJD. From the European perspective, a 
collaborative sUldy aimed to provide comparative epidemiological 
data that would enable baseline epidemiological parameters to be 
established which might be crucial to the assessment of the risk of 
CJD in relation to animal spongiform encephalopathies.3 In this 
chapter we will address the methods and general design of the 
Dutch register and the collaborative stlldy on CJD conducted in 
Europe from 1993 until 1995.,·4,5 
3.2 Diagnostic criteria 
All patients described in this thesis were classified according to 
conunon diagnostic criteria adapted from those originally pro-
posed by Masters et aI, shown in tables 1 and 2 (overleaf).6,7 
Whenever possible the classification upon inclusion into the study 
was reviewed after new results of clinical or post mortem exam-
inations became available. 
Definite CJD included those patients that were confirmed by 
neuropathology with the classic triad comprising spongy de-
generation of the cerebral grey matter, neuronal loss and the 
proliferation and hypertrophy of astrocytes and/or by immu-
nocytochemical staining of pri~n protein. 
• Probable CJD included patients who had a classical clinical 
course defined as a rapidly progressive dementia and a typical 
electroencephalogram (generalised periodic sharp wave activ-
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Table 1 - Diagnostic criteria for CJD in the collaborative European studies.6 
Sporadic 
I. Definite 
2. Probable 
3. Possible 
NeuropathoJoglcally confirmed andlor 
Immunocytochemically confirmed PrPsc positive! Western blot> and/or 
Scrapie associated fibres 
Progressive dementia 
Typical EEG 
At least 2 out of 4 clinical features listed 
Progressive dementia 
At least 2 out of 4 clinical features 
No EEG or atypical EEG 
Duration less than 2 years 
Clinical features: 
!. Myoclonus 
2. Visual or cerebellar 
signs 
3. PyramIdal or extra· 
pyramIdal signs 
4. AkInetic mutism 
Iatrogenic 
1, Progressive cerebellar syndrome In a pituitary hormone recipient, or 
2. Sporadic CJD with a recognized exposure risk. 
Genetic 
I. Definite or probable CJD plus definite or probable CJD in a first degree relative, or 
2. Neuropsychiatric disorder plus CJD-spec1fic PRNP mutation. 
Table 2 - Diagnoslic crileria for CJD by Maslers el al.7 
1. Transmissible virus dementia 
Experimentally transmitted to nonhuman primates andlor other animals, producing an 
experimental sponglform encephalopathy. 
2. Definite or probable CJD 
2a Definite 
2b Probable 
Neuropatho[oglcally confirmed, and 
At least 1 of the following 5 cUnlcal features 
listed 
Progressive dementia, and 
At least 2 out of 5 clinical features listed, and 
No neuropathological confirmation available 
Clinical features: 
I. Myoclonus 
2, Pyramidal signs 
3, Characteristic EEG 
4. Cerebellar signs 
5. Extrapyramidal signs 
3, Possible CJD 
20 
Progressive dementia with: 
Myoclonus and duration less than three years, or 
A relative with a transmissible, definite or probable CJD, or 
At least 2 out of 5 clinical features listed, together with signs of lower motor neuron 
involvement 
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ity occurring at I-2Hz) and at least two out of the following 
specific clinical features: myoclonus, visual or cerebellar signs, 
extra-pyramidal or pyramidal signs, akinetic flmtisJll. 
• Possible qD included those patients who had a history of a 
progressive dementia with a duration less than two years and 
at least three of the above-mentioned clinical features but 
without the typical EEG changes or neuropathological confir-
mation. 
Furthermore, cases were classified according to the pathogenesis 
or aetiology of the disease. 11uee types were distinguished. 
Iatrogenic qD was defined as 0) progressive cerebellar syn-
drOIne in a pituitary hormone recipient or (2) sporadic CJD 
with a recognized exposure risk. 
• Genetic C]D was defined as (1) definite or probable CJD plus 
definite or probable CJD in a first degree relative or (2) neuro-
psychiatric disorder plus disease-specific PRNP mutation. 
Sporadic CJD was defined as a case of unknown origin, I.e. 
non genetic and non iatrogenic. 
Ascertainment study population 
For the collaborative studies on incidence, risk facors and survival 
different study populations, comprising sporadic, genetic and 
iatrogenic GJD patients, were derived from the national registries. 
11,e incidence study comprised all definite and probable patients 
with year at onset (n-570) or death (n-606) in the three year 
period 1993 to 1995. For the case control study all definite and 
probable CJD patients with disease onset in the four year period 
1992-1996 were eligible. However, per country only a proportion 
of those eligible, were finally included (n-405) in the case-control 
study. For the survival analysis all definite and probable patients 
with year at onset in the three year time period 1993 to 1995 
(n-606) were eligible and included. 
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Netherlands and Belgium 
11,e data collection was coordinated by the Department of Epi-
demiology & Biostatistics of the Erasmus University Medical 
School in Rotterdam. the Netherlands and the Department of Neu-
rology of the University Hospital Rotterdam, Dijkzigt in Rotterdam, 
the Netherlands. 11,e study population comprised two countries, 
the Netherlands (study period January 1, 1992 to December 31, 
1995) and the Dutch speaking part of Belgium (Flanders; study 
period January 1,1994 to December 31,1995). In the Netherlands 
neurologists, (neuro)pathologists and those in training, in total 835 
physicians, were sent requests to notify us all known or suspected 
cases of GJD with onset of disease or death from January 1, 1993 
onwards (see appendix). Each centre was asked to assign a con-
tact person, in total 160 neurologists, whom we repeatedly (two to 
three times a year) contacted by mail and telephone. 11,e Flemish 
speaking part of Belgium was included in the study from JanualY 
1, 1994. For Flanders 250 neurologists, (neuro)pathologists and 
those in training were sent requests to notify suspected cases of 
GJD. A total of 191 neurologists were assigned as contact persons. 
Referred patients were seen by a research physician, sometimes 
repeatedly, and their clinical and EEG records were reviewed. 
During the course of the illness the clinical records, EEG records, 
vital status and pathology records of the patients were reassessed. 
We reconunended recording of serial EEG's and performing in-
vestigations as CT and MRI scan to exclude other possible causes 
of dementia. We encouraged and discussed the iluportance of 
post mortem examination and the precaution methods to be taken 
to reduce the potential risk of contamination. After obtaining in-
fornled consent from the patientls relatives, blood was taken for 
prion protein gene analysis. TIle genetic screening for coding 
mutations or non-encoding polymorphism at codon 129 of the 
PRNP gene was performed in St Mary's Hospital, in London, (Prof. 
J. Collinge). When the patient was known to us only through 
neuropathology, hospital notes where obtained and EEG record-
ings were examined. In most cases the post mortenlS were per-
formed in the hospital where the patient was diagnosed. A 
number of patients were referred to a university hospital for 
second opinion. Neuropathology was reviewed by one neuro-
3.3.2 
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pathologist (Dr G.H. Jansen) with immunohistochemical staining 
techniques. 
111e Dutch and Belgian registries asceltained 48 newly diagnosed 
cases and 44 mortality cases in the three year period from 1993 to 
1995. A total of 49 patients were eligible for the case-control 
sOldy, of whom 43 (88"10) were included. Reasons of non-response 
to the case-control study were lack of cooperation of relatives 
(four) and no informed relative avallabl~ (two). One control 
subject was selected for each case. Control subjects were recnlited 
by questioning ward staff. Patients with a neurodegenerative dis-
order were excluded. Matching criteria were sex, age (+/- 5 
years), and hospital of admission. Information on cases and 
control subjects was obtained through a stnlCtured interview with 
an informant. In each matched set relatives of an identical degree 
were interviewed whenever possible. 
EU collaborative study 
In 1993 a project for coordination of national CJD surveillance 
programmes was fi.lflded by the European union, linking already 
established national registries in France and the UK and proposed 
national registries in Germany, Italy, the Netherlands and Flanders 
(project-leaders: Dr R.G. Will and Prof. A. Hofman). 
The objectives of the European collaborative sOldy were (J) to 
sOldy the frequency of C,JD In Europe in relation to the occurrence 
of BSE, (2) to assess the risk of C,JD in relation to genetic, occupa-
tional and nutritional factors, with particular emphasis on animal 
spongiform encephalopathies and (3) to smdy the clinical course 
of C,JD. 
For this purpose the European collaborative sOldy was carried out 
in three parts: (J) registries of C,JO were established in 6 European 
countries, (2) a case-control sOldy of risk factors for CJO was per-
formed on the basis of cases in the registries and (3) molecular 
genetic sOldies of CJO with material collected in the registries 
were conducted. 
1be method of case ascertainment was through direct notification, 
mainly from neurologists and was similar to previous epidemiol-
ogical surveys of C,JO.8.14 111e registries included sporadic, genetic 
and iatrogenic CJD. The aim of the registries was to achieve a 
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complete ascertainment of al1 cases emerging in a defined geo-
graphic area and to serve as a basis for further epidemiologic and 
molecular genetic snldies. Prion protein gene analysis on blood or 
frozen brain tissue was performed in national genetic laboratories 
to screen for mutations and a polymorphism at codon 129 of the 
PRNP gene. 
France 
TI,e data collection was coordinated by Unit 360 of the Institute 
National de la Sante et la Recherche (INSERM), Paris. 11Ie French 
registry ascertained 148 newly diagnosed cases and 150 mortality 
cases in the three year period from 1993 to 1995. For the case-
control study 194 patients with definite or probable CJD were 
eligible of whom 75 09"10) were included in the case-control 
study. One control subject was selected for each case, matched for 
age (+/- 5 years) and sex. Information on cases was obtained from 
an informant, mainly a next of kin. A relative of a non-CJD patient 
admitted at the same hospital served as a control subject, with the 
non-CJD patient acting as the informant for the control. 
Germany 
11Ie data coordinating centre for the snldy was the Department of 
Neurology of the Georg August University of Gtittingen, Germany. 
11Ie German registry ascertained 155 newly diagnosed cases and 
123 mortality caseS in the three year period from 1993 to 1995. For 
the case-control snldy 162 patients with definite or probable CJD 
were eligible of whom 136 (84%) were included in the case-
control snldy. One control subject was selected for each case. 
Matching criteria were sex, age (+/- 5 years) and hospital of 
admission. Excluded as control subjects were patients with 
dementia or any other disorder of the central nervus system. 
Information on cases and control subjects was obtained through a 
stnlctured Interview with an informant. 
Italy 
'The general case ascertainment for the registry was coordinated 
by the Laboratorio di Virologica, Instituto Superiore di Sanita, 
Roma. Coordination of the case-control snldy was carried out by 
the Department of Neurology of the Universita Cattolica del Sacro 
Methods 
Cuore, Rome. The Italian registry ascertained 114 newly diag-
nosed cases and 98 mortality cases In the three year period from 
1993 to 1995. For the case-control study 123 patients with definite 
or probable C]D were eligible of whom 63 (51%) were Included 
in the case-control study. Matching criteria were sex, age (+/- 5 
years) and hospital of admission. Information on cases and control 
subjects was obtained through a stmctured Interview with an 
informant. Information on cases and control subjects was obtained 
through a stnlctured interview with an informant. 
United Kingdom 
The data collection was coordinated by the national C)D surveil-
lance Centre at the Western General Hospital, Edinburgh, UK. The 
British registty ascertained 138 newly diagnosed cases and 141 
mortality cases in the three year period from 1993 to 1995. For the 
case-control study 153 patients with definite or probable C)D were 
eligible of whom 88 (58",1,) were included in the case-control 
study. One control subject was selected for each case, matched for 
age (+/- 5 years), Sex and hospital. Control subjects were selected 
from the neurological ward with exclusion of any neuro-
degenerative disorder or from a non-neurologic ward. Control 
subjects were recmlted by questioning ward staff excluding those 
with a neurodegenerative disorder. For cases data were obtained 
from a relative. For controls, this procedure was followed when-
ever possible. 
Slovakia 
111e data collection was coordinated by the Institute of Preventive 
and Clinical Medicine in Bratislava. 111e registry of Slovakia as-
certained ten newly diagnosed cases and seven mortality cases in 
the three year period from 1993 to 1995. Cases from Slovakia 
were not Included In the collaborative case-control study. 
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Table 3 - Clinical, genetic and pathological characteristics of CJD studied 
Neurological signs and symptoms 
at onset / during course 
Investigations & 
prian protein gene 
analysis 
Pathological 
post mortem / 
biopsy 
Dementia Sensory EEG Nerve cell loss 
Cerebellar Vertigo/dizziness CT-scan Gliosis 
Visual/oculomotor Pseudobulbar MRI scan Spongiform change 
Pyramidal 
Extrapyramidal 
Seizures 
Involuntary 
movements 
Myoclonus 
Headache 
3.4 
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Neurogenic muscle CSF Immunostaln!ng 
wasting lFT Western blot 
Akinetic mutlsm PRNP mutation SAF 
Galt disturbances PRNP polymorphism 129 
Speech disturbances 
Visual disturbances 
Forgetfulness 
Data collection 
Clinicopathologic features 
For all patients the clinical course of disease was studied. Neuro-
logical signs at onset and during the course, and symptoms 
reported by patient's relatives were assessed from medical 
records. In table 3 the clinical features, investigations and pathol-
ogical characteristics assessed are sununarised. 
Sporadic, genetic and iatrogenic patients with definite or probable 
CJD with onset of disease during the period January 1, 1993 to 
December 31, 1995 were eligible for studies on stllvival and 
clinical course (n=606). Duration of illness was defined from first 
symptoms till death or censoring date at May 31, 1996. Using data 
and material collected in the national registries, clinical and 
molecular genetic studies were carried out with the aim to 
improve diagnostic criteria 15·17 for C]D and to study the role of the 
PRNP gene.1B -22. 
Table 4 - Risk factors studied for CJD 
Medical history Familial history Exposure 
Surgery CJD Occupational 
Overall Overall exposure to 
Bra/n I sf degree relative patients/patient 
Vertebral column Grandparents material 
Other surgety Overall exposure 
central nervous Dementia to paNents/ 
sytem Overall body tIssue 
I sf degree relative Physic/an 
Blood transfusion Grandparents NeuropathologIst 
Nurse 
Organ 
Parkinson's Laboratoty transplantation disease technIcian Dentist 
Disease history Overall Ambulance worker 
Epilepsy 1st degree relative 
Treatment Grandparents Occupational ex-
psychlatrist/ posure to animal 
psychologist products 
Jaundiced Butcher 
Glandular fever Slaughter 
Poflo Vetetinaty doctor 
Herpes Zoster Meat/food 
Herpes Simplex processor 
Rheumatoid Leather worker 
arlhritis Animal/animal 
Diabetes products 
Allergies/atopy 
HeadlnjUlY Occupational 
Medical 
exposure to 
animals 
treatments/tests 
EMG 
HusbandlY 
Cows 
Lumbar punctlon Sheep 
Acupuncture Pigs 
Vaccination Horses 
Hom1One suppl Other cattle 
Opthalmologlst/ MInk/ferrets 
optician test Other fur animals 
Dentist visit Deer/elk 
Other animals 
Methods 
Animal (product) Consumption 
exposure 
Domestic expo- Meat and milk 
sure to animals products 
Cats Sausage 
Dogs Raw mea! 
Rodents Raw fish 
Birds Products animal 
Rsh blood 
Snakes Milk 
Otherpets Cheese 
General exposure O,.gan meat 
to animals and Tripe 
animal products KIdney 
Contact with fur/ Liver 
leather other Brain 
than through Eye 
clothes 
Lived on a fam1 Meat 
Ferlllizer 
. arllficlal f. Beef 
. hoofs + homs Veal Lamb 
Leather worker Polk 
Bone meal 
Dried blood of 
animals 
Ever bitten by 
animal 
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Case-control study 
To study risk factors of CJD a case-control study was performed 
with cases froHl the registries including cases with onset of disease 
from 1992 onwards. Definite and probable patients with sporadic, 
genetic or iatrogenic CJD were eligible for the case-control study. 
Data collection on possible risk factors was obtained through a 
structured Intelview by a research physician with an informant, in 
most cases a next of kin. To achieve symmetrical data collection, 
information on risk factors of the control subject was also obtained 
through an interview with an informant. 
For the collaborative study a standardised core questionnaire on 
risk factor exposure was developed to be used In all participating 
countries. lbe core questionnaire was adapted from a question-
naire used in the ongoing epidemiological surveillance in the 
UK. 23 Data collected using the former questionnaire (in Italy and 
the UK) were mapped to the European format. A computer data-
entry programme was developed based on the core questionnaire. 
Data were centralised and analyzed at the Department of Epide-
miology & Biostatistics of the Erasrnus University in Rotterdam. 
111e risk factors that were investigated are sUlluuarised in table 4 
(page 27). 
Statistical analysis 
Incidence 
Cases were included according their diagnostic status on May 31, 
1996. Sporadic, iatrogenic and genetic cases classified as definite 
or probable CJD have been included in the analysis. Mortality 
rates were estimated using all deaths from CJD in the period 1993 
to 1995. Mortality rates (cases/million/year) were estimated for 
each countlY and overall for the collaborative smdy. Incidence 
was estimated based on patients newly diagnosed with CJD in the 
period 1993 to 1995. 'TI,e demographic data used for estimating 
the denominators are shown in table 5. 24 
Methods 
Table 5a - Population denominators (in millions)' 
Belgium France Germany Italy 
7.1 57.7 81.2 57.1 
Nether-
lands 
15.3 
Slovakia 
5.3 
UK 
58.2 
t Denominator derived from Population Trends, winter 1996;188ue 33:table 5a 
Table 5b - Population in 10 year age bands !in thousands)' 
France Germany Italy Netherlands UK 
< 39 32759 42517 32332 8942 31687 
40-49 7303 10166 7448 2128 7591 
50-59 5754 10572 7121 1521 6021 
60-69 5453 7691 6341 1302 5011 
70-79 3197 5059 3669 871 4091 
> 80 2145 3008 1866 434 2021 
t Denominator figures derived from Demographic Year Book by the United Nations 1991:33: 
table 5b 
3.5.2 Case-control study 
1his analysis was based on the original raw data of the five parti-
cipating centres: Netherlands/BelgiulU, France, Gernlany, UK, and 
Italy. Principal investigators of the studies were invited to Rotter-
dam to coordinate the strategy of analysis in the four major topics 
and reported their results at the fifth meeting of the collaborative 
EU study on CJD, held in Edinburgh in May 1996. TIle strength of 
association between CJD and putative risk factors was assessed by 
computing the odds ratio (OR) as an estimate of the relative risk. 
Relative risks were estimated by maximum likelihood methods 
and the 95% CI were based on the asymptotic standard errors. 
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Two different strategies were followed in the analysis. First, all 
analyses were conducted using an unconditional logistic regres-
sion model. Confounding by age, sex and study centre was taken 
into account by including these variables into the regression 
Illodel. Second, we performed an analysis using a conditional 
logistic regression model which took into account the matched 
case and control pairing. This design is in accordance with the 
matched desIgn of the study however at the expense of statistical 
power. A major problem resulting from the second approach is 
the loss of information in that a matched set of case and control 
was dropped out of the analysis if data were missing on a variable 
in either case Of control. Therefore risk estimates may be biased 
due to selection. As both strategies gave similar findings judged 
upon the relative risk estimates, findings of the method wIth the 
highest statistical power, the unconditional analyses, are given. In 
order to test for effect modification by significant differences 
between study centre, in both strategies an interaction term with 
the risk factor studied was included into the model. 
Stratified analyses were perfonnecl based on sex, age at onset, 
diagnosis (probable versus definite), family history of CJD, PRNP 
mutations and polymorphism at codon 129 of the PRNP gene. For 
each risk factor, we repOit the number of subjects exposed and 
the total number of subjects for whom data on the risk factor were 
available. 
Survival 
[n the studies of sUlvival, only patients with definite and probable 
CJD were included. 11,e aim was to estimate (J) median duration 
of disease from onset to death and (2) the death risk ratios for 
different clinical and genetic subgroups. Kaplan-Meier survival 
curves and log rank tests were used to estimate median survival 
On tnonths) and to compare survival. 25,26 A Cox1s proportional 
hazards model was used to compute cmde and adjusted death 
rate ratios. 27 \Ve adjusted for possible confounders as sex, age, 
classification (probable versus definite) and study centre. Both 
methods take into account the fact that not every patient was fol-
lowed until death due to termination of the follow-up of patients 
on May 31, 1996. Stratified analysis was performed for the pres-
Methods 
ence of a PRNP mutation and for diagnosis (probable versus defi-
nite). 
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ERASMUS UNIVERSITEIT ROTTERDAM 
FACULTEIT DER 
GENEESKUNDE EN 
GEZONDHEIDS-
WETENSCHAPPEN 
dr. Mol~<lterpldn 50 
I~st~u!il 
Epidemiok>gie 
en Biostat'stiek 
Uw Brief Om icenmuk Datum 
AH/dw 93.2704 26 mei 1993 
Onderwerp F,nnumrmr Dvorkiesnummu 
Jakob-Creullfeldl Fax 010-408 7494 7481 
Zeer geachle collega, 
In sommige Europese landen is 'Uees geuit voor een mogelijk verband (ussen de ziekte van 
Jakob-CreulzfeJdt bij de mens en de spongioforme encephalopathie bij dferen zoals scrapie en 
BSE. Het is daarom van belang de risico-factoren van deze zeldzame ziekle Ie bestuderen. 
Zoals u we1licht weel word! in Grool-Briltanie al enkera jaren epidemiologisch onderzoek naar 
de ziekte van Jakob-Creulzfeldt verricht Nu zal in Europees verband een pali!!nt-conlrole 
onderzoek worden uitgevoerd waarin ook Nederland zal participeren, om zo In twee jaar een 
voldoende aantal patienten te verkrijgen. De uitvoering hiervan in Nederland zal geschieden 
door de afdelingen Neurologie en Epldemiologie van de Erasmus Universiteit en het Acade-
misch Ziekenhuis Dijkzigt Ie Rotterdam, in samenwerking met het R.I.V.M. Ie Bilthoven. 
Graag zouden wij ow medewerking willen wagen: 
. om een register op Ie zeHen van paMnten mel de ziekte van Jakob-Creutzfeldt gezien vanaf 
01-01-93 door neurologen in Nederland . 
. om bij deze paUenlen een patient-conlrole onderzoek uit Ie voeren (hiervoor verwijzen wij u 
naar bijgaand artikel). 
Voor hel opbouwen van hel register verzoeken wi; u het bljgaand antwoordkaartje te 
retourneren of contact op Ie nemen mel de onderzoekcoOrdinator, mew. D.P.W.M. Wienljens, 
arts (telefonisch te bereiken onder lelefoonnummer 010-4087481 tussen 10 en 12 uur 's 
ochtends). 
Wlj vragen u iedere patient die u verdenkt van de ziekle van Jakob-Creutzfeldl aan Ie melden. 
Vanzelfsprekend zullen wij u van de resunaten van hel onderzoek op de hoogte houden en zijn 
wij Ie allen lijde bereld evenluele wagen van uw kant Ie beantwoorden. 
Bij voorbaat onze hartelijke dank voor uw medewerking. 
Mel vriendelijke groet, 
Prof. Or. A. Hofman 
Afd. Epidemiologie 
Po,tadres: Po,tbu> 1738 3000 DR Rouerdam 
Prof. Or. F.G.A. van der Meche! 
Afd. Neurologie 
Te!efoon 010 - 4()8 1111 
Patient-controle onderzoek naar de ziekte van Jakob-Creutzfeldt 
In een patient-controle onderzoek zullen mogelijke oorzaken en risico-factoren 
van de ziekte van Jakob-Creutzfeldt worden bestudeerd. Het onderzoek zal 
twee jaar dUren. ledere patient die u verdenkt van de ziekte van Jakob-
Creutzfeldt komt in aanmerking vear het onderzoek. Wij verzoeken u daarorn 
aile patienten die u verdenkt, aan te melden! De onderzoekcoordinator zal 
vervolgens uw kliniek bezoeken en een vragenlijst afnemen bij een familielid 
van de patient. Er zal ondermeer gevraagd worden naar vleesconsumptie, het 
houden van dieren en doorgemaakte operaties. Veor elke patient zal een 
conlrole-patienl geselecleerd worden uit dezelfde kliniek. Daarnaasl zal in 
overleg met u eventueel bleed voor verder onderzoek worden afgenomen. 
Daar de ziekte van Jakob-Creutzfeldt een uiterst zeldzame ziekte is en 
mogelijk niet aile verdachte pati~nten met deze ziekte spontaan aangemeld 
zullen worden, willen wij voorsteHen dat wij elke twee maanden een 
contactpersoon in uw kliniek telefonisch benaderen om te informeren of u een 
patient heeft aan te melden. 
Gelieve het bijgaande strookje te retourneren, ook indien u geen patient met 
de ziekte van Jakob-Creutzfeldl heeft gezien. 
Antwoordstrookje 
Vanaf 1 januari 1993 heb ik palienten gezien verdacht van de zlekte van Jakob-Creutzfeldt 
Ja I neen 
Voor onze klinlek treedt op als contaclpersoon voor het patient-controle onderzoek 
Naam: 
Ziekenhuis: 
Adres: 
Plaals 
TeLldoorkiesnr.: 
Opmerkingen: 
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Abstract 
National registries for Creutzfeldt-Jakob disease (CJD) were estab-
lished in 1993 (or earlier) in France, Germany, Italy, 11,e Nether-
lands, Slovakia and the United Kingdom (UK). In 1994/1995 
registries were also established in Spain and part of Belgium. 
Between 1993-1995 cases of CJD were Identified in participating 
countries using identical methodologies and were classified ac-
cording to agreed diagnostic criteria. 570 cases of definite or 
probable CJD died in the study period with an overall annual 
mortality rate of 0.73 cases/million. lbe incidence and mortality 
rates for CJD are allnost similar because of the short median 
duration of illness of about four months. nle incidence rates for 
C]D were similar in all participating countries despite variations in 
post-11101tem rates, and age-specific incidence rates were also 
relatively consistent, with the exception of an increased incidence 
of CJD in patients aged <39 years in the UK. In relation to etiol-
ogical subtypes of CJD, 90% of cases were sporadic, INn genetic 
and 2% iatrogenic. Genetic forms of CJD accounted for 80% of all 
cases in Slovakia and iatrogenic forms of CJD occurred Jll.ost 
frequently in France and the UK. 111e data in this paper establish 
baseline epidemiological parameters for CJD in palticipating 
European countries, which may be important in the asseSSJuent of 
any future change in the characteristics of CJD as a result of the 
epidemic of bovine spongiform encephalopathy (BSE). 
Incidence 
Introduction 
Epidemiological research into Creutzfeldt-Jakob disease (CJD) has 
shown that the disease is rare, with a worldwide distribution. A 
causal link with scrapie in sheep or goats is unproven I. The pos-
sibility that bovine spongiform encephalopathy (BSE) might rep-
resent a greater risk than scrapie to the human population has led 
to a range of legislative measures in the UK and elsewhere in 
Europe and the recommendation of the Southwood conunittee2 
for a systematic study of CJD in the UK. Although BSE has occur-
red only at low incidence in other European countries, including 
France, Germany and Italy, there has nonetheless been extensive 
concern about the potential implications for public health. 
Historical data on the epidemiological and other characteristics of 
CJD are available in the UKl , France', Italy' and Slovakia6, but 
comparison with contemporaty data in order to identify any 
change related to BSE might be compromised by improved case 
ascertainment and scientific advances, for example prion protein 
(PRNP) gene analysis. In order to obtain contemporalY compara-
tive data on CJD, a system for harmoniSing the research method-
ologies of national surveillance systems for CJD was established in 
1993 and included France, Germany, Italy, the Netherlands, Slo-
vakia and the United Kingdom (UK). 11,e primalY aim of this pro-
gramme was to identify any change in the characteristics of CJD 
that might correlate with exposure of the human population to 
BSE and thereby indicate a causal link between animal and hu-
man prion diseases. 
Methods 
11,e European Union (EU) collaborative study of CJD was initiated 
in 1993. National registers for CJD had been established in the UK 
in 1990, in France in 1992 and in Slovakia in the 1970s. Similar 
registers were set up in Italy and the Netherlands in Januaty 1993 
and in Germany in May 1993. In 1994 and 1995 registers were 
established in Spain and in part of Belgium (Flanders). 
39 
CHAPTER 4 
Results 
40 
1he aim of the national registers was to identify all Incident cases 
of C]D, to obtain detailed clinical information on all cases and to 
study putative risk factors for C]D through a case-control study. 
Cases were ascertained primarily by direct referral from targeted 
professional groups including neurologists, neurophysiologists 
and neuropathologists. In each country all members of these pro-
fessional groups were circulated at the start of the study and at 
regular intelvals through the study period and asked to notify any 
suspect case of CJD. Detailed information was obtained in the 
great Inajority of cases by a research worker who visited the refer-
ral centre and In cases notified after death by review of the case-
notes. Cases were classified according to conunon diagnostic cri-
teria7 adapted from those originally proposed by Masters et al.B 
Whenever possible blood was obtained for DNA analysis and de-
tails of the PRNP genotype were available in 6SOAl of all cases. 
As this was a prospective study, the time at which case classifica-
tion is possible varies according to the availability on information 
on clinical features and in particular on neuropathological con-
firmation of the diagnosis, which may not be available for months 
after death. For the analyses in this paper cases were included 
according to the diagnostic status on May 31, 1996. Cases classi-
fied as definite or probable have been included in analysis. Inci-
dence rates were calculated based on patients diagnosed with C]D 
In the period 1993-1995. Mortality rates were estimated using all 
deaths from C]D in the period 1993-1995. 
Incidence / mortality rates of CJD 
n,e Incidence and mortality rates for C]D are almost similar be-
cause of the short median duration of il1ness of about four 
months. However in the first year of this prospective study, 
1110ltality rates may have been underestimated because clinically 
incident cases were identified and some deaths may have been 
missed. In the last year of the study some incident cases will not 
be included in analysis because of inevitable delays in obtaining 
neuropathological Information. 1his effect has been minimised by 
Incidence 
Table 1 a - Total numbers of cases per year. by date of death. 
Belgium France Germany Italy Neth. UK Slovakia Total 
1993 0 39 16' 32 11 44 3 145 
1994 5 53 56 35 18 56 5 228 
1995 6 58 51 31 8 41 2 197 
Overall 11 150 123 98 37 141 10 570 
* Extrapolated from part year data 
Table 1 b - Total numbers of cases per year. by date of onset of disease. 
Belgium France Germany Italy Neth. UK Slovakia Total 
1993 43 45' 40 13 47 2 191 
1994 7 55 54 35 15 56 4 226 
1995 2 50 56 39 6 35 189 
Overall 10 148 155 114 34 138 7 606 
* Extrapolated from part year data 
delaying final classification of cases incident in 1995 to May 31, 
1996. Table 1 lists the number of cases of CJD classified by year. 
One hundred and ninety-one cases of CJD were identified with 
disease onset in 1993, compared with 145 deaths. There were 197 
deaths from CJD in 1995 In comparison to 189 cases with disease 
onset In that year. Overall there were a lower number of deaths 
from CJD (570) than clinically incident cases (606). All further 
analyses of this chapter are based on mOltality from CJD. 
Mortality rates for CJD are listed in Table 2 (overleaO. The overall 
annual mOltality rate for CJD in Europe is 0.73 cases/million and 
the rates in individual countries range from 0.57 (Italy) to 0.87 
(France). 111ere is a greater range of mortality rates in analyses by 
year and study site with a high figure of 1.18 cases/million in 1994 
in the Netherlands and a low figure of 0.38 in 1995 in Slovakia. 
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Table 2 - Mortality rates (cases/million/year) in Europe from 1993-1995' 
Belgium France Germany Italy Neth. UK Slovakia Total 
1993 0.68 0.79" 0.56 0.72 0.74 0.57 0.68 
1994 0.71 0.92 0.68 0.61 1.18 0.95 0.94 0.85 
1995 0.86 1.00 0.57 0.54 0.52 0.67 0.38 0.85 
Overall 0.78 0.87 0.67 0.57 0.81 0.78 0.63 0.73 
Denominators figures derived from Population Trends, winter 1996 Issue;33:table Sa 
Extrapolated from part year data 
11,is may reflect the small population size in the Netherlands and 
Slovakia, resulting in unstable risk estimates. Overall, however, 
there is relative consistency in mortality rates both with time and 
between countries. nle proportion of cases of suspect CJD in 
which necropsy is performed might influence mortality rates for 
CJD. 111e post mortem rate varied among countries with 41% in 
France, 52% in Italy, 65% in the Netherlands, 66% in Germany, 
73% in Belgium, 86% in the UK and 100% in Slovakia. Further-
more, there was marked variation between countries in the ratio 
definite to probable cases of C]O: in Italy and France there was an 
excess of probable cases (70% and 63%, respectively) in contrast 
to Germany, the Netherlancis, Belgium, the UK and Slovakia, with 
an excess of definite cases (53%, 65%, 70%, 88"/0 and 100%, 
respectively). There was an overal1 excess of female cases (ratio 
female:male = 1.4:1) with little variation between countries. 
Table 3 - Total cases by aetiological sub-
Cases of CJO can be classified 
according to three clinical 
subtypes: sporadic, genetic/ 
familial and iatrogenic. 11,e distri-
bution of cases according to 
aetiology is listed in Table 3. 11,e 
proportions of aetioiogical sub-
types are computed from the 
entire sample of patients with 
CJO (~570). Ninety per cent of 
cases were classified as sporadic, 
type in Europe, 1993-1995. 
Sporadic Genetic Iatrogenic 
1993 127 13 5 
1994 205 19 4 
1995 179 13 5 
Overall 511 45 14 
(90%) (8%) (2%) 
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8% as genetic and 2% as iatrogenic. TI,e proportion of genetic 
cases was 120/0 if they are computed from the sample with PRNP 
analysis. The proportions of subtypes of CJD was heterogeneous 
between countries. 111ere were no iatrogenic cases identified in 
the smdy period in Itaiy, the Netherlands, Belgium or Slovakia, 
while 6% of cases in the UK were iatrogenic. A relative excess of 
genetic cases were identified in France (12%), Italy (13%) and 
Slovakia (80%) and no such cases were identified in the 
Netherlands or Belgium. The percentage of cases with DNA 
analysis also varied between countries, with 90% cases analyzed 
in Slovakia, 80% in Germany, 78% in France, and 66% in Italy, 
compared to 580/0 or less in other countries. 
PRNP codon 129 genotype was available in 341 cases: 74% were 
homozygous for the methionine allele, 16% were heterozygous 
and 10% were homozygous for the valine allele. TI,e relative pro-
portions of genotype at codon 129 of the PRNP gene were consis-
tent between countries with the exceptions of the Netherlands 
(n~18) with 22% homozygous and 22% heterozygous for the 
valine allele, and Slovakia (n~7) with 43% homozygous and 57% 
heterozygous for the methionine allele. 
Age at onset of disease was available in 560 cases. The age-
specific mortality rates overall and by country are shown in table 4 
and figure 1 (overleaf). The peak mortality of CJD occurred in the 
70-79 year age group with a decline in the >80 year age group. 
111e age distribution of cases was similar in all countries with the 
exception of a peak mortality in the 60-69 year age group in Italy, 
a high rate in the 40-49 and 50-59 year age groups in the Nether-
lands, and a relative increase in the mOltality rate in the UK in 
cases aged less than 39 years, with a rate of 0.14 cases/million 
representing at least twice the mortality of CJD in this age group 
in relation to any other country. With regard to the small numbers 
of patients in Belgium and Slovakia, the age-specific rates for 
these countries are not computed nor included in table 4 and 
figure 1. 
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Table 4 - Age specific mortality rates/year/million in Europe, 1993-1995' 
<39 40-49 50-59 60-69 70-79 >80 
France 0.03 0.27 2.03 3.30 4.48 1.39 
Germany 0.02 0.10 0.90 1.69 2.44 0.55 
Italy 0.03 0.18 1.17 2.21 1.20 0.36 
Netherlands 0.07 0.63 1.54 2.56 4.21 2.33 
UK 0.14 0.26 1.16 3.26 3.42 0.99 
Overall 0.05 0.22 1.25 2.53 3.06 0.88 
t Denominator figures derived from Demographfc Year Bo.ok by the United Nations 1991 ;33: 
table 5b 
o France 
1m Germany 
[[l] Italy 
iii Netherlands 
I!!l UK 
• Overall 
5.00 ..................................................... , ... . 
4.00 
3.00 
2.00 
1.00 
0.00 l-_"",--,lkI!BWm 
<39 40·49 SO·59 60·69 70·79 
Figure 1 - Creutzfeldt-Jakob disease in Europe 1993-1995. Age-specific inciden· 
ce rates (cases/million) 
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11,is is the largest systematic survey of CJD, including data from 
national registers in Belgium, France, Germany, Italy, the Nether-
lands, Slovakia and the UK. Participating countries have wide 
variations in the provision of health care, notably in relation to the 
numbers of professionals who have been targeted to provide noti-
Incidence 
fication of cases of suspect CJD. An important question is whether 
the data from these countries is tntly comparable. An important 
assumption In CJD surveillance is that incident cases of CJD will 
be referred for a neurological opinion and/or will undergo invest-
igation including electroencephalogram and necropsy. Available 
evidence suggests that the great majority of cases of CJD can be 
identified by the study methodology utilised by all countries in 
this study9 and that case-identification rests on the overall level of 
awareness of targeted professional groups rather than simply the 
overall numbers of such individuals. to Of particular concern is the 
wide variation in necropsy rates between countries. This would 
tend to result in a relative increase in apparent incidence in 
countries with higher necropsy rates because a higher proportion 
of cases in which a diagnosis could not be made on clinical 
grounds would be reported. 111is effect is minimised if, as in this 
study, active efforts are made to obtain detailed clinical informa-
tion on evelY suspect case and it is of interest that cases of CJD 
have been identified throughout all regions of participating coun-
tries. 
11,e most important finding in this study is the remarkable consis-
tency in the mortality rates for CJD In participating countries. 
111ere is some variation from year to year and the high incidence 
of CJD in 1994 may reflect a higher level of case ascertainment 
than in other years due to the inclusion of cases Incident in 1993 
and 1994 and with necropsy information available in the great 
majority by May 31st, 1996. 11,e continuing study of CJD (funded 
for 1997-1999) will allow the systematic accumulation of data on 
incidence and Illoltality which will remove year-on-year biases. 
'The Incidence of BSE is orders of magnitude higher in the UK 
than in any other participating country and there is no correlation 
in this study between the overall mortality rates for CJD and the 
incidence of BSE. However, significant but minor changes in the 
characteristics of CJD might not be reflected by analysis of mOltal-
ity rates alone. 
Other analyses in this study, including the frequency of clinical 
subtypes of CJD, the sex distribution of cases and the frequency of 
genotypes at codon 129 of the PRNP gene are consistent with 
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previous data on CJD.3,1l+14 Analysis by countlY has shown some 
differences between countries in these variables. 111e relative ex-
cess of genetic forms of CJD in France and Italy may reflect, at 
least in part, the higher proportion of cases with available genetic 
information in these cQuntries,12,13 111e vety high frequency of 
genetic cases in Slovakia has long been recognised and may be 
due to genetic isolation." 111e gene frequency at codon 129 of the 
PRNP gene confirms a great excess of methionine hOluozygotes in 
comparison to the normal genotype distribution at this locus. 111e 
unusual codon 129 distribution in the Netherlands and Slovakia is 
unexplained but may reflect the small numbers of cases analyzed 
in these countries. 
Overall, the age-specific mortality rates for CJD are as expected,·4 
with an increase in incidence up to middle age and highest J110f-
talit), rates in the 60-69 and 70-79 year age-groups. 111e mortality 
rates in the very elderly are higher than expected in all countries 
and it is possible that this reflects improved ascertainment of cases 
in this population. Another important finding is the high relative 
incidence rate in the youngest age group «39 years) in the UK, 
which is even more marked if the age distribution is analyzed by 
age at onset of disease. 111is excess is due to the occurrence of 
iatrogenic cases of CJD at a higher rate than in other countries and 
to the occurrence of new variant CJD. 16 Indeed the availability of 
contemporaty comparative data on the incidence of CJD in the 
younger population was cmdal to the hypothesis that these cases 
might be causally linked to BSE. 
'DIe collaborative study of CJD in Europe has allowed compara-
tive information on the clinical, pathological and epidemiological 
characteristics of C]D to be defined. While the evidence for a 
causal link berween BSE and CJD is weak in this study, the pro-
longed Incubation periods in prion diseases indicate that BSE-rela-
ted changes in mortality of CJD could still occur. Recent evi-
dence l7 has strengthened the hypothesis that there may be a 
causal link berween BSE and new variant ClD and the availability 
of this baseline information m.ay be of crucial importance in the 
interpretation of data from continuing epidemiological research in 
Europe. 
Incidence 
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Risk factors 
Abstract 
We have studied risk factors for Creutzfeldt-Jakob disease (CJD) as 
part of the 1993-1995 ED collaborative studies of CJD in Europe. 
Patients with definite or probable CJD (N~405) were derived from 
population-based studies conducted in the period 1993 to 1995 in 
Belgium, France, Germany, Italy, the Netherlands and the United 
Kingdom. Patients were compared to 405 hospital controls. We 
found significant evidence for familial aggregation of CJD as well 
familial aggregation of CJD with dementia due to other causes 
than CJD. A significant increased risk of CJD was found for sub-
jects exposed to domestic birds, leather products and fertilizer 
consisting of hoofs and horns. Of the dietary factors studied, the 
consumption of brain and raw meat were associated with an in-
creased risk of CJD. In the period studied, no association could be 
shown between the risk of CJD and to the consumption of beef, 
veal. lamb, cheese or milk. 
Risk factors 
Introduction 
Creutzfeldt-Jakob disease (CJD) Is the most Important prion disor-
der In humans. I•2 CJD has been transmitted from man to man 
through human growth and gonadotropin hormone,3-6 neurosur-
gery and EEG electrode implantation,7-10 and corneal transplanta-
tion. II However, iatrogenic transnlission has been found to be rare 
in case series2 as well as in a fe-analysis of case-control studies of 
risk factors for CJD conducted in Japan, 12 the United States13-14 and 
the United Kingdolll. 15•16 Prion disease may be endemic in live-
stock including sheep (scrapie) and cows (bovine spongiform en-
cephalopathy [BSED. 11,e aforementioned re-analysls of case-con-
trol studies conducted in the period 1975 to 1984 failed to show 
statistically significant evidence for transmission from cattle to 
human. '6 However, the discovery of a new variant of early-onset 
CJD in the United Kingdom following the BSE epidemic has re-
opened the discussion whether prion disorders may be transmit-
ted from cattle to human through aniJual contact or the consump-
tion of meat (products). In a number of cases CJD Is Inherited. I 
Various dominant mutations in [he prion protein gene (PRNP) on 
chrolllosome 20 have been identified that may cause CJD. 1,17 Fur-
thermore, subjects homozygote for the codon 129 polymorphism 
of PRNP have been shown to be at increased risk of CJD. 18•19 In 
addition to familial aggregation of CJD, there is also evidence for 
familial clustering of CJD with dementias other than CJD and with 
Parkinson's disease. 16 
In the period 1993-1995, we have conducted a collaborative study 
of risk factors for CJD in Europe. Here, we repOlt the findings of 
the risk factors studied, including genetic factors, medical and oc-
cupational histOlY, animal exposure and diet. 
Patients and methods 
111e EU collaborative studies of CJD were initiated in 1993. 
National registries for CJD had been established in the UK, France, 
and Slovakia before 1993. Similar registries were set up In other 
European countries in 1993 and 1994. 11,e aim was to monitor the 
incidence of CJD and to study risk factors. Population-based 
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studies were started in Belgium, France, Germany, Italy, the 
Netherlands and the United Kingdom.20 A standardised diagnostic 
work-up as well as a standardised core questionnaire on risk 
factor exposure was used. 111e studies aimed to ascertain all 
patients diagnosed with definitive or probable C]D according to 
the criteria adapted from those described by Masters et al,21 living 
in a defined geographical area. 20 Here, we present the overall 
findings of the case-control study conducted in the period 1993-
1995. 11,e study population differs from that of the incidence 
studies in that we included patients diagnosed with CJD in the 
period 1992-1995.20 A total of 405 (199 definite and 206 probable 
C]D) were included in the case-control studies presented here. 
111e patients series comprised 154 men and 251 women. In 9 
patients, the onset of C]D was below the age of 40 years, in 190 
between 40 and 64 years and in 206 at age 65 years or later. Be-
low, for each site data-collection for the case-control studies of 
risk factors will be discussed briefly. Studies are in alphabetical 
order based on the name of the countly. 
Belgium/Netherlands 
11,e data coordinating centre for the study was the Department of 
Epidemiology & Biostatistics of the Erasmus University Rotterdam, 
the Netherlands. 111e study population comprised two countries, 
the Netherlands (study period January 1, 1992 to December 31, 
1995) and the Dutch speaking part of Belgium (Flanders; snldy 
period JanualY 1, 1994 to December 31, 1995). A total of 49 pa-
tients with probable Of definite CJD were ascertained,20 of whonl 
43 (88010) were included in the case-control snrdy. 111e 43 patients 
were matched according to sex and age (+/- 5 years) to controls. 
Control subjects were derived from the neurological ward at 
which the matched patient was diagnosed. Excludeel subjects 
were controls with a history of dementia Of other neurodegenera-
tive disorder. Data were collected by the standardised question-
naire of the collaborative EU smelies. For cases and controls the 
data were obtained from a next of kin. 
Risk factors 
France 
111e data collection was coordinated by Unit 360 of the Institut 
National de la Sante et de la Recherche (INSERM), Paris. In the 
period January 1, 1992 to December 31, 1995, 194 patients with 
probable or defInitive CJD were ascertained.20 Included in the 
case-control study are 75 (390/0) patients. 111e patients were 
matched according to sex and age (+/- 5 years) to controls. For 
the data collection I a structured interview based on the standard-
ised protocol of the collaborative EU CJD studies was used. For 
cases the data were obtained from a next of kin. A relative of a 
non-CJD patient at the hospital served as a control subject, while 
the non-CJD patient served as the informant for this control sub-
ject. 11ms, for controls data on risk factor exposure were also ob-
tained from an informant. 
Germany 
111e data coordinating centre for the study was at the DepartInent 
of Neurology of the Georg August University of Goltingen, Ger-
many. In the period January 1, 1992 to December 31, 1995, 162 
patients with probabie or definitive CJD were ascertained.20 Of 
these patients, 136 (84%) were included in the case-control study. 
111e 136 patients were matched according to sex and age (+/- 5 
years) to controls. Control subjects were derived from the same 
hospital as the matched case. Excluded were patients with a histo-
ly of dementia or other neurodegenerative disorder. Data were 
collected by a research physician using a structured intelview 
based on the standardised protocol of the collaborative EU CJD 
studies. For cases and controls the data were obtained from a next 
of kin. 
Italy 
111e data coordinating centre for the study was at the Department 
of Neurology of the Universita Cattolica del Sacra Cuore, Rome. In 
the period January 1, 1992 to December 31, 1995, 123 patients 
with probable or definite CJD were ascertained from the study 
region," of whom 63 (51%) were included in the case-control 
study. 111e 63 patients were matched according to sex and age 
(+/- 5 years). Control subjects were derived from the same 
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hospital where the patient was diagnosed. Data were collected by 
an interview based on the standardised protocol of the collabor-
ative EU C]D studies. For cases and controls the data were 
obtained from a next of kin. 
United Kingdom 
11,e data collection was coordinated by the C]D Surveillance Cen-
tre based at Western General Hospital Edinburgh, Scotland. In the 
period JanuaIY 1, 1992 to December 31, 1995, 153 patients with 
probable or definite CJD were ascertained,20 of whom 88 (58''10) 
were included in the case~control study. 111e patients were 
matched to controls according to sex and age (+/- 5 years). Con-
trol subjects were derived from the neurological ward where the 
C]D patient was diagnosed. Data were collected by a structured 
interview by a physician. 11,ese data were mapped to the stand-
ardised questionnaire of the collaborative EU C]D studies. For 
cases the data were obtained from a next of kin. For controls, this 
procedure was followed whenever possible. 
Statistical Analysis 
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11,is analysis is based on the original raw data of the five paltici-
pating centres: Netherlands/Belgium, France, Germany, Italy, and 
the UK. 11,e data were centralised at the Department of Epidem-
iology & Biostatistics of the Erasmus University Rotterdam. 
Principal investigators of the studies were invited to Rotterdam to 
coordinate the strategy of analysis in the four major topics, (1) 
genetic factors (Drs Alperovitch and Laupr~tre, France), (2) medi-
cal history (Dr Zerr, Germany), (3) occupational history and ani-
mal exposure (Dr Will, UK), and (4) diet (Dr Masullo, Italy). 
The strength of association between CJD and putative risk factors 
was assessed by computing of the odds ratio (OR) as an estimate 
of the relative risk.23 Relative risks were estimated by maximum 
likelihood and the 95 confidence intervals (95% CI) were based 
on the asymptotic standard errors. We followed rwo different 
strategies in the analyses. First, all analyses were conducted using 
an unconditional logistic regression model, taking the matching 
Results 
Risk factors 
variables age, sex and study centre into account by including 
these variables in the regression model. In this way, maximum use 
was made of the data available. Secondly, we performed an 
analysis using a conditional logistic regression model in order to 
take the matching variables into account. Although this analysis is 
in accordance with the matched design of the study, a major 
problem was the loss of information in that a matched set of cases 
and controls was dropped out of the analysis if data were missing 
on a variable in either the case or the control. As a consequence, 
the statistical power of the conditional analysis was low and risk 
estimates may be biased due to selection. As both 'strategies gave 
similar findings judged upon the relative risk estimates, findings of 
the method with the highest statistical power, the unconditional 
analyses, are presented here. 
In both strategies, significant differences between study centres 
were tested for by including an interaction term with the risk fac-
tor studied into the model. Furthermore, stratified analyses were 
performed based on sex, age at onset, diagnosis (probable versus 
definite), family history of CJD, PRNP mutations and poly-
morphism at codon 129 of the PRNP gene. However, details on 
these stratified analyses and on specific exposures are not dis-
cussed here but will be published separately. 
Family histolY of CJD, dementia and Parkinson's disease was 
studied in siblings, parents and grandparents (table 1, overleaO. 
For seven patients included in the case-control study, a positive 
family history of CJD was repOlted. A positive family history of 
dementia other than CJD was found significantly more often in 
CJD patients than in controls. The risk of C./D for those with a first 
degree relative with dementia due to antoher cause than CJD was 
found to be 2.26 (95% CI: 1.31-3.90). Although a family history of 
Parkinson's disease was reported more often for CJD cases, the 
difference between cases and controls was not significant 
(p=0.07). 
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Table 1 - Family history of CJD, dementia and Parkinson's disease and the risk 
ofCJD 
Exposure frequency Odds Ratio 
Family history cases controls crude adjusted' 
CJD 
Overall 7/358 0/311 12.0" 
10.70·219.481 
First degree relatives 71358 0/311 
Dementia other than CJD 
Overall 54/358 22/311 2.33' 2.35+ 
[1.39·3.931 [1.38·3.991 
First degree relatives 50/358 21/311 2.24+'* 2.26+'* 
[1.31-3.831 [1.31-3.901 
Parkinson's disease 
Overall 13/289 51285 2.64 2.79 
10.93·7.501 OL97·8.051 
First degree relatives 13/289 51285 2.64 2.79 
10.93·7.501 [0.97·8.051 
I Adjusted for age, gender,country, 95% Clln parentheses 
+ p < 0.05 
... P < 0,01 by Fisher exact test 
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Medical histories of patients and controls are compared In table 2. 
Significantly fewer cases than controls had a history of surgery 
and blood transfusion. Specifically a history of surgery of the ver-
tebral column was found less often among CJD patients, while 
there was a non-significant increase in the risk of CJD associated 
with surgery of the brain and organ transplantation. nlere was no 
significant evidence for an association of CJD to any of the disor-
ders studied in the medical history including psychiatric history, 
infectious disorders and head trauma (see table 2). A history of 
EMG and iumbar punction was found significantly less in GJD 
cases than tn controis. 
with regard to occupational history, the exposure to human tissue 
through contact with patients and patient materiais as well as the 
exposure to animal products and animais was evaluated (table 3, 
p. 59). None of these factors were Significantly associated to the 
risk of GJD. 
Risk factors 
Table 2 - History of surgery and the risk of CJD 
Exposure frequency 
(at CJD diagnosis) Odds ratio 
History cases controls crude adjusted! 
Surgery 
Overall 315/400 342/405 0.68+- 0.69+-
10.48-0_981 10.49-0.991 
Bra!n 12/400 71405 1.76 1.77 
10.69-4.511 [0.68·4.611 
Vertebral column 17/400 31/405 0.54+- 0.53' 
[0.29-0.981 [023·0.981 
Other surgery central 2/400 2/405 1.01 1.03 
nervous system [0.14-7.221 [0.14-7.401 
Eye 33/401 34/406 0.98 0.96 
[0.59-1.621 10.57 -1.591 
Blood transfusion 38/341 71/378 0.54+- 0.56+ 
10.35-0.831 10.37·0.971 
Organ transplantation 6/284 2/282 3.02 3.01 
10.60-15.11 [0.61-15.221 
Disease history 
Epilepsy 14/398 171400 0.82 0.87 
10.40-1.691 10.42-1.691 
Treatment psychiatrist! 69/399 55/401 1.32 1.38 
psychologist [0.89-1.931 10.92-2.071 
Jaundiced 44/364 43/374 1.06 1.06 
10.68-1.661 10.67-1.671 
Glandular fever 9/306 13/317 0.71 0.53 
10.30-1.681 10.21-1.351 
Polio 3/367 4/367 0.75 0.74 
10.17-3.371 [0.16·3.351 
Herpes zoster 54/330 63/340 0.86 0.86 
10.58·1. 281 [0.55-1.361 
Herpes simplex 64/167 65/180 1.10 1.14 
[0.71-1.701 10.71-1.841 
Rheumatoid arthritis 20/171 21/180 1.00 0.99 
[0.52-1.921 [0.50-1.951 
Diabetes mellitus 21/182 33/192 0.63 0.63 
[0.35-1.131 [0.34-1.141 
Allergies/Atopy 411158 33/166 1.41 1.44 
[0.84-2.381 [0.84-2.461 
Head injury 66/394 54/400 1.29 1.33 
[0.87-1.901 [0.89·2.001 
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Tabl. 2 - continued 
Exposure frequency 
(at CJD diagnosis) Odds ratio 
History cases conlrols crude adjusted1 
Medical treatments/tests 
EMG 9/162 26/176 0.34+ O.32~ 
10.15·0.751 10.14·0.721 
Lumbar punction 38/188 40/144 0.66 O.49f 
10.40·1.101 10.28·0.871 
Acupuncture 59/393 76/400 0.75 0.74 
10.52·1.091 10.50·1.091 
Vaccination 109/379 114/385 0.96 0.95 
10.70·1.311 10.68·1.321 
Hormone supplements 41/313 30/320 1.46 1.50 
10.88·2.401 10.89·2.541 
Ophthalmologist/optician 188/351 210/379 0.93 0.96 
test 10.69·1.241 10.68·1.351 
Dentist visit last year before 173/339 164/343 1.14 1.15 
onsetCJD 10.84·1.541 10.84·1.5]] 
I Adjusted for age, gender,countfy, 95% Ciin parentheses 
• p < 0.05 
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When studying domestic exposure to animals (table 4, p. 61), a 
significant increase in risk of CJD was found for subjects exposed 
to domestic birds (OR 1.55; 95% CI: 1.09-2.19). Of the general ex-
posures to animals and animal products Ctable 4), contact with 
leather products other than through clothes was associated with a 
1.87 (95% CI: 1.11-3.15) fold increase in the risk of CJD. Exposure 
to dried blood, animal bites or having lived on a farm was not as-
sociated with CJD. Exposure to the fertilizer consisting of hoofs 
and horns was reported significantly more often for patients than 
controls (OR 2.26; 95% CI: 1.35-3.77). 
11,e relation between diet and the risk of CJD Is sUlllluarised in 
tables 5 (p. 62) and 6 (p. 63). Table 5 shows the association be-
tween consumption of several animal products and the risk of 
CJD. 111e consumption of raw meat products was significantly 
associated with an increased risk of CJD. ll1ere was no significant 
Risk faclors 
Table 3 - Occupational history and animal exposure and the risk of CJD 
Exposure fr'equency Odds Ratio 
Exposure 
cases controls crude adjusted! 
Occupational exposure 
patients or patient material 
Overall exposure to 32/397 35/404 0.92 0.92 
patients / body tissue £0.56· 1 .531 £0.55· 1.531 
Physlcfan 3/397 1/404 3.05 3.03 
10.32·29.471 10.31·29.501 
Neuropathologist 0/397 0/403 
Nurse 16/394 211402 0.77 0.75 
10.39· 1.491 10.38·1.481 
Laboratory technician 3/397 2/404 1.54 1.53 
£0.26·9.251 10.25·9.421 
Dentist 0/397 1/402 0.34 
£0.01·8.291 
Ambulance worker 0/397 0/404 
Occupational exposure 
animal products 
Overall exposure to 73/395 75/402 0.98 0.98 
Animals/animal products 10.69· 1.411 £0.68· 1.421 
Butcher 7/392 5/401 1.44 1.44 
£0.45·4.581 10.45·4.621 
Slaughter 2/347 2/354 1.02 1.05 
10.14·7.281 10.14·7.871 
Veterinary doctor 0/393 0/401 
Meat/Food processor 9/347 9/354 1.02 1.01 
10.40·2.601 10.39·2.611 
Leather worker 2/347 2/354 1.02 1.01 
10.14·7.281 10.14·7.331 
Occupational exposure 
animals 
Husbandry 57/393 51/349 1.16 1.17 
£0.77·1.741 £0.77·1.771 
Cows 43/344 38/354 1.19 1.20 
10.75· 1 .891 10.75· 1.391 
Sheep 23/343 23/354 1.03 1.05 
10.57·1.881 10.57· 1.931 
Pigs 26/330 28/346 0.97 0.97 
10.56· 1.691 10.55· 1.701 
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rable 3 - continued 
Exposure frequency Odds Ratio 
Exposure 
controls crude adjusted1 cases 
Horses 17/326 14/340 1.28 1.31 
[0.62·2.641 [0.63·2.751 
Other cattle 2/331 2/343 1.04 1.04 
[0.15·7.401 10. 14·7.481 
Mink/Ferrets 1/395 2/402 0.51 0.51 
[0.05·6.621 [0.05·5.651 
Other fur animals 2/336 3/349 0.69 0.68 
[0.11·4.161 [0.11·4.191 
Deer/elk 0/343 0/353 
Other animals 20/395 14/398 1.46 1.45 
[0.73·2.941 10.71·2.941 
I Adjusted for age, gender, country, 95% CI in parentheses 
60 
evidence for a dose response relation between the consumption 
of raw meat and the risk of CJD. For subjects for whom a con-
sumption pattern was described as one time a year, the relative 
risk was 2.32 (95%CI:0.86·6.26), while the relative risk for con-
sumption several times a year was 1.11 (95%CI:0.60-2.03), for 
once a month 2.08 (95% CI: 1.08-4.00), for once a week 2.08 (950/0 
CI: 0.69-6.30) and for each day 0.58 (95% CI:0.05-6.42). 11,e 
consumption of raw beef (45/391 in cases and 31/394 in contfOls) 
was more common than that of raw pork (18/405 in cases and 
13/405 in controls). Raw beef consumption was associated to a 1.5 
fold (95% CI: 0.94-2.46) increase in risk. 111e risk associated with 
the consumplion of raw pork was very similar (OR 1.40; 95% CI: 
0.68-2.80), Brain consumption was associated with an increased 
risk of CJD (OR 1.68;95% CI: 1.18-2.39). The relative risk of CJD 
associated with the consumption of bovine brain was 1.56 (95% 
CI: 0.68-3.51). None of Ihe meat products studied, such as sausage 
and black pudding was associated to the risk of CJD. Finally, 
when analyzing the data on meat consumption, there was no 
evidence for a significant association of CJD to the consumption of 
beef, veal, lamb or pork (table 6), except for the consumption of 
pork once a week. 
Risk factors 
Table 4 - Domeslic exposure and general exposure to animals and animal 
producls exposure and Ihe risk of CJD 
Exposure frequency Odds ratio 
Exposure 
cases controls crude adjustedl 
Domestic exposure to 
animals 
Cat 158/353 155/352 1.02 1.03 
10.77·1.391 10.77·1.401 
009 196/354 196/354 1.02 1.02 
10.76·1.381 10.76·1.391 
Rodent/Hamster 43/353 36/353 1.22 1.22 
10.76·1.951 [0.76·1.961 
Bird 100/342 73/346 1.55+ 1.56+ 
[1.09·2.191 [1.09·2.231 
Fish 44/355 32/352 1.41 1.44 
[0.87·2.291 [0.87·2.391 
Snakes 14/355 81354 1.78 1.91 
[0.74·4.291 [0.75·4.841 
Other pets 27/339 20/344 1.38 1.40 
[0.76·2.521 10.75·2.601 
General exposure animals 
and animal products 
Contact with fur/leather 42/392 24/398 1.87+ 1.94+ 
other than through clothes [1.11·3.151 [I. 13·3.33J 
Lived on farm 153/395 142/399 1.14 1.15 
[0.86·1.531 [0.85·1.541 
Fertilizer 116/381 1081390 1.14 1.15 
[0.84·1.56J 10.83·1.601 
. Artificial fertilizer 24/302 32/318 0.77 0.76 
[0.44·1.341 10.43·1.371 
. Hoofs and horns 48/366 24/383 2.26' 2.32' 
[1.35·3.771 11.38·3.901 
Bone meal 57/358 46/374 1.35 1.41 
[0.89·2.051 10.90·2.211 
Dried blood of animals 28/403 32/405 0.87 0.96 
[0.51·1.471 [0.56·1.641 
Ever bitten by anImal 29/128 35/151 0.97 0.97 
[0.55·1.701 [0.55·1.701 
I Adjusted for age, gender,cQuntry. 95% CI In parentheses 
• p < 0.05 
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Table 5 - Consumption of organ, meat and milk products and the risk of CJD. 
Exposure frequency Odds ratio 
Consumption animal 
cases controls Crude Adjusted l products 
Meat and milk products 
Sausage 382/400 3811403 1.23 1.22 
10.65·2.321 [0.64·2.341 
Raw Meat 143/391 1071394 1.55' 1.63+ 
[1.14·2.091 [1.18·2.231 
Raw fish 24/131 20/143 1.38 1.53 
10.72·2.641 [0.72·3.231 
Products anImal blood 2061269 1901262 1.24 1.24 
[0.84·1.841 [0.80·1.921 
Milk 292/307 290/313 1.54 1.57 
[0.79·3.021 [0.79·3.121 
Cheese 321/332 329/339 0.89 0.89 
10.37·2.121 [0.37·2.141 
Organ meat 
Tripe 152/387 155/393 0.99 1.00 
10.75·1.321 [0.70·1.421 
Kidney 176/383 175/398 1.08 1.10 
[0.82·1.441 [0.80·1.511 
liver 3171391 310/395 1.18 1.18 
10.83·1.661 10.83·1.691 
BraIn 49/115 37/118 1.63 1.68+ 
10.95·2.781 [1.18·2.391 
Eye 4/316 2/332 2.12 2.12 
10.38·11.631 [0.38·11.901 
1 Adjusted for age, gender,cQuntry, 95% CI In parentheses 
+ p < 0.05 
Discussion 
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In this collaborative study of risk factors of CJD, we found evi-
dence for familial aggregation of CJD as well as familial aggrega-
tion of CJD with dementia due to other causes. With regard to the 
exposures to animals and animal products studied, a significant 
increase in risk of CJD was found for subjects exposed to domes-
tic birds, leather products and fertilizer consisting of hoofs and 
horns. Of the diet3lY factors studied, the consumption of brain 
and raw meat were associated with an increased risk of CJD. No 
Table 6 - Consumption of meat and the risk of CJO. 
Beef Veal Lamb Pork 
Frequency 
cases controls odds ratio cases controls odds ratio cases controls odds ratio cases controls odds ratio 
Never 7 12 reference 102 121 reference 91 91 reference 7 9 reference 
<1 time/year 10 10 56 62 1.07 31 41 0.76 7 17 
[0.68-1.671 [0.44-1.311 
Several times/yr 38 30 1.64 85 78 1.28 45 38 1.18 32 35 1.70 
[0.74-3.621 [0.85-1 .91l [0.71-1.881 [0.76-3.81l 
1 time/month 154 175 1.14 97 97 1.19 20 26 0.77 128 145 1.64 
[0.58-2.221 [0.81-1.741 [0.40-1.481 [0.82-3.27J 
1 time/week 182 169 1.39 44 35 1.49 8 3 2.67 213 186 2.13' 
[0.72-2.71l [0.89-2.50] [0.68-10.37J [1.08-4.14J 
1 time/day 5 5 1.29 1.19 6 5 2.23 
[0.32-5.21l [0.07-18.20] [0.58-8.621 
• p<0.05 
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association was found to the consumption of beef, veal, lamb, 
cheese or milk In these analyses. SurgelY of the vertebral column, 
blood transfusion, EMG and lumbar punction were inversely as-
sociated to the risk of CJD. 
When interpreting the findings, a number of methodological 
issues are to be kept in mind. Although the study aimed to be 
population based, the inclusion rate of cases in the case-control 
study of (known) patients at the paIticipating sites varied from 
390;6 to 880/0. Response rates in controls are not known. Thus, 
findings may have been distorted if the response rate in cases 
and/or controls was associated to the factor(s) studied. Further, 
the use of hospital controls may have introduced selection bias in 
that exposure frequencies to surgery, medical disorders and/or 
treatments may not be representative for the general population. 
\Vhen excluding controls ascertained from neurological wards, 
there was no significant difference between CJD patients and 
controls found for surgery of the veltebral column (OR 0.82; 95% 
CI: 0.24-2.84), EMG (OR 5.36; 95% CI 0.38-74.70) or lumbar 
punction (OR 4.50; 95% CI 0.83-24.50) suggesting the inverse 
association may be explained in palt by the control selection. 
When considering bloocl transfusion ten years before the inter-
view, a period aetiologically relevant given the long incubation 
period of CJD, no significant clifference was found between cases 
and controls in the hlstOlY of blood transfusion (OR 0.76; 95% CI 
0.40-1.26). 111is suggests the inverse association between a histolY 
of blood transfusion and CJD may be explained in part by the 
increased frequency for this putative risk factor in hospital con-
trols, who lUay have been admitted specifically fOf surgery. 
With regard to information bias, it Is important to note that all clata 
on risk factor exposures were collected retrospectively from a sur-
rogate informant for cases. 111is may have reduced the validity of 
the information. In some instances, the control subject was inter-
viewed in person, which may have introduced a systematic differ-
ence between the cases and controls. For all putative risk factors, 
the clata were therefore analyzed including only patients and 
matched controls for whom the data were obtained from a next of 
kin. Another source of information bias may have been recall bias, 
Risk factors 
Le., because of the devastating effects of the disease, informants 
of patients may have been tnore willing to consider putative 
exposures in the past than informants of controls. Important 
determinants of this type of bias are the time between the onset of 
CJD and the interview and the vital status of the patient at the time 
of the interview. Data were therefore stratified according to the 
vital status of the patient and the time between onset of CJD and 
the interview. None of these analyses change the conclusions of 
the analysis presented. 
As expected given the dominant mutations that have been impli-
cated in CJD,I.17 our study shows familial aggregation of CJD. Our 
study confirms earlier findings of familial aggregation of CJD with 
other dementias,16 A family history of Parkinsonls disease was 
repOlted lUore often for CJD cases. However, no significant differ-
ence could be shown between cases and controls. Although PRNP 
mutations have been found in in a number of patients with fa-
milial forms of dementia 19,22, it is unlikely that the occurrence of 
dementia in the relatives of CJD patients can be fully explained by 
PRNP mutations. Other genetic Of non-genetic factors may under-
lie the relationship. 11,e most important candidate gene is the 
apolipoprotein E gene which has been associated to Alzheimer's 
disease and various types of dementia as well as CJD.24,25 
In agreement with earlier findings, iatrogenic transmission of dis-
ease appears to be rare and no significant increased risk of CJD 
related to the medical histOlY, Induding organ transplantation and 
blood transfusion, could be shown in this large population-based 
sample of CJD patients. However, there is reason to interpret 
these findings with caution because of the limited validity of our 
study due to the use of hospital controls. Both the magnitude as 
weB as the direction of associations of CJD to surgelY and blood 
transfusion could be explained for a large part by the use of 
hospital controls. 111ese findings indicate that further studies on 
iatrogenic transmission using population-based controls and well 
defined incubations periods are necessary. nle present study 
failed to confirm the association between history of psychotic 
disease and the risk of CJD obselved in a pooled analysis of case-
control studies conducted in the period 1975 to 1984.16 
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with regard to the exposure to animals and animal products, the 
consumption of brain as well as raw meat were associated with an 
increased risk of CJD. nlese findings may be explained by the fact 
that the concentration of prions in affected animals is expected to 
be highest in brain tissue and spinal cord and although prions are 
resistant to temperature, concentrations are expected to be higher 
in raw meat compared to cooked meat. nle absence of a dose-re-
sponse relationship between the consumption of raw meat and 
the risk of CJD makes a cause-effect relationship less likely. Fur-
thennore, a significant increase in risk of CJD was found for 
subjects with domestic birds and those exposed to fertilizer 
consisting of hoofs and horns. For each of these findings, a 
plausible biological explanation is lacking and these findings 
remain to be confirmed in future experimental and observational 
studies. Findings on exposure to leather were inconsistent as no 
association was found to occupational exposure (table 3) while a 
significant association was found to general exposure (table 4). 
No evidence was found for an increase in risk of CJD associated 
with the (occupational) exposure to cattle. One of the findings of 
our study with the most Impol1ant public health implications is 
that in the period studied, there was no association of CJD to the 
consumption of beef, veal or lamb. Although this finding is com-
patible with the view of no transmission of prion disease from 
cattle to humans through the consumption of Bleat, our sntdy is 
limited to patients diagnosed at or before 1995. AI; the first pa-
tients with new variant CJD26, an atypical form of CJD that has 
been related to the BSE epidemic in the UK27, were described in 
1995, we have to await funue snldies to detennine whether 
consumption of beef/veal from animals infected with prion dis-
ease may increase the risk of new variant CJD. In particular count-
ries in which ESE occurred may yield crucial information when 
compared to those countries without ESE. 
Risk factors 
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CHAPTER 
Prognosis 
Abstract 
TI,e prognosis of patients with Creutzfeldt-Jakob disease (CJD) 
was studied in a series of cases identified froIu a European col-
laborative study on CJD. A total of 606 cases were ascertained 
through direct notification, mainly. by neurologists and were 
classified as definite and probable according to common diagnos-
tic criteria. TIle information on clinical feaulres was obtained from 
examination and medical records. Prion protein gene (PRNP) 
coding sequence analysis was performed in 434 subjects with 
CJD. Duration of illness was defined from first symptoms to death 
or censoring date. Statistical comparisons were performed using 
Kaplan-Meier survival cUlves, log rank tests and Cox!s propor-
tional hazard analysis. 
In our SUJdy of 606 CJD patients the median sUlyival was four 
months and gender and early age at onset were impOitant prog-
nostic factors. Most clinical features were not related to survival. 
In contrast to earlier findings, mortality was significantly increased 
in patients with a PRNP mutation andlor a positive family hlstOlY 
for CJD (death rate ratio (DDR) 1.23; 95% confidence interval 
(95% CO 1.01-1.49). Among patients without a mutation in the 
prien protein gene (PRNP), mOltality among carriers of valine at 
codon 129 was significantly lower (DRR 0.66; 95% CI 0.54-0.79 for 
heterozygous, and DRR 0.67; 95% CI 0.55-0.81 for homozygous). 
This study does not provide evidence for a clinical subgroup of 
CJD that relates to smyival except for the new variant of CJD. 'n,e 
finding that sporadic CJD carriers of at least one valine allele at 
codon 129 of the PRNP gene had an increased smYlval, highlights 
the influence of genetic factors In the pathophysiology and pro-
gnosis of prion diseases. 
Prognosis 
Introduction 
11,e term 'Creutzfeldt-Jakob disease' (CJD) was first used by 
Spielmeyer in 1922" bringing together the original case repOlt by 
Creutzfeldt in 19202 with subsequent patients described by Jakob.3 
CJD belongs to the group of transmissible spongiform encephalo-
pathies, which may occur in a sporadic, inherited or iatrogenic 
form. CJD is a neurodegenerative disorder, clinically recognized 
by the occurrence of a rapidly progressive dementia with myo-
clonus, which may be accompanied by cerebellar ataxia and other 
neurological Signs. 11,e electroencephalogram (EEG) may show 
characteristic pseudoperiodic sharp wave activity. 111e clinical 
course is usually rapid and many patients die within a few months 
of onset:' Although the vast majority of patients have a duration of 
illness of less than 12 months, around 10% of patients with CJD 
present atypically with a longer duration of illness.,·6 A prolonged 
duration has been reported in CJD associated with PRNP 
mutations7-10 and in the recently described new variant of CJD. 1I ,12 
Little is known about other factors predicting survival in 
CJD.3,6,7,I3,14 Clinical characteristics associated with survival may 
yield impOltant clues for the definition of clinical subgroups in 
CJD including the new variant of CJD. 11,e polymorphism at 
codon 129 of the PRNP gene plays a key role in the pathogenesis 
of, and susceptibility to, sporadic, inherited and iatrogenic 
CJD.7.9.I5.,9 In this report we study 606 patients from six different 
European countries to evaluate the importance of various clinical 
and genetic features as predictors of mortality. 
Materials and Methods 
Patients selection 
This study is based on a collaborative European study on CJD.20•21 
In 1993 a project for coordination of national CJD sUlveillance 
programs was started linking already established registries in 
France and the UK to new registries in Germany, the Netherlands, 
Italy and Belgium .. Incident sporadic, genetic and iatrogenic CJD 
patients were ascertained with year at onset of disease from 1993 
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to 1995.22,23 ll1e method of case ascertainment was based on a 
common protocol in participating countries. All centres aimed to 
asceltain all patients with GJD in a defined population by direct 
notificatIon of any clinically suspect case, mainly by neurologists 
and by the use of death certificates and neuropathology as a 
safety net. Pathologically confirmed cases were identified by di-
rect notification from neuropathologists. CJD cases were classified 
as definite or probable according to diagnostic criteria adapted 
from Masters et a1. 24 nle diagnosis of definite cases was neUl'opa-
thologically confirmed, exhibiting spongy degeneration of the 
cerebral grey matter, neuronal loss and proliferation and hypertro-
phy of asu'ocytes and/or by immunocytohlstochemical staining for 
prion protein." Probable cases had a rapidly progressive demen-
tia, a typical electroencephalogram (EEG) with periodic sharp 
wave activity and at least two out of four specific clinical features 
(luyoclonus, visual or cerebellar symptoms, extrapyramidal or 
pyramidal symptoms, akinetic mutism). Iatrogenic patients with a 
known source of accidental contamination as human pituitaty 
growth hormone, corneal graft or dura mater graft recipients were 
also included in the analysis. Prion protein gene analysis on blood 
or frozen brain tissue was performed in national genetic laborato-
ries to screen for ulUtations and polymorphism at codon 129 of 
the PRNP gene. We defined genetic GJD as cases with a neuro-
psychiatric disorder and a disease specific PRNP mutation and/or 
individuals with a positive family history of GJD. 
Clinical assessment 
CJD patients with an onset of disease during the period JanualY 1, 
1993 to December 31, 1995 were eligible for the study. Referred 
patients were visited and examined by a research physician and 
blood was taken for prion protein gene analysis. Duration of 
illness was defined as the period from first symptoms to death Of 
the censoring date at May 31, 1996. 11,e clinical and EEG records 
of the patients were reviewed in each case in order to obtain 
information on the clinical signs reported by the neurologist and 
for symptoms related to the present Illness reported by the 
patientts relatives. During the course of the illness the clinical 
records, EEG records, vital status and pathology records of the 
patients were reviewed. \Ve studied the concomitant occurrence 
Prognosis 
of clinical features earlier described in clinical subgroups of 
CJD.4,6,1l,12 
Statistical analysis 
Kaplan-Meier survival curves and log rank tests were used to es-
timate and to compare survival. 26,27 Cox's proportional hazards 
Blodel was used to compute clude and adjusted death rate ratios 
(DRR).28 We adjusted for possible confounders, including gender, 
age, classification as probable and country of residence. Both 
methods take into account the fact that not every patient was fol-
lowed until death due to termination 
of the follow-up of patients on May 
Table 1 - Descriptive summary of 31, 1996. 
CJD patients from the collaborative 
European study. 
Number % Results 
------------------
Patients 
Country 
Belgium 
France 
Germany 
Italy 
Netherlands 
United KIngdom 
Slovakia 
Definite 
Typical EEG 
Men 
Age at onset 
mean (sd) 
median 
range 
Duration (months) 
mean (sd) 
median 
range 
Aetiology 
606 
10 
148 
155 
114 
34 
138 
7 
338 
471 
241 
64.1 (11.6) 
65.1 
16.3-92.2 
6.1 (5.7) 
4.0 
0-35 
1.7 
24.4 
25.6 
18.8 
5.6 
22.8 
1.2 
55.8 
77.7 
39.8 
Descriptive summary 
Numerical data for the total of 606 
patients are presented in table 1. Of 
the 606 patients 365 were female 
(60.2%). Duration from first symptom 
to death or to censoring date ranged 
from less than one to 35 months; 50% 
of the patients died within four 
months. Age at onset of illness ranged 
from 16 to 92 years (mean 64.1 years). 
Genetic patients (n-40) accounted for 
9.2% of the cases in which PRNP 
genotype was available. 11,ere Were 
40 genetic cases with a mutation of 
the PRNP gene of whom 330/0 had a 
positive family histolY of C]D. At the 
censoring date 63 of the 570 patients 
genetic patients 40 9.2'" were still alive. 
Iatrogenic 12 2.0 
'" percentage of total number tested 
(n~434) 
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Table 2 - Survival in patients with Creu!zfeldt·Jakob disease 
Number 
Overall 606 
Gender 
men 241 
women 365 
Age at onset 
<40yrs 27 
40--64 yrs 271 
>64 yrs 308 
Median 
(in 
months) 
4 
4 
5 
10 
5 
4 
Death rate ratio' 
crude adjusted' 
1.21' 11.01·1.44) 1.25' 11.04·1.49) 
reference reference 
0.51' 10.42·0.60 0.36'10.30·0.43) 
0.91' 10.76·1.09) 0.78' 10.65·0.93) 
reference reference 
Classification 
definite 
probable 
Typical EEG 
+ 
338 
268 
471 
107 
4 
4 
4 
6 
reference reference 
0.75' 10.63·0.89) 0.71' 10.59·0.85) 
0.9810.82·1.17) 0.9810.83-1.18) 
reference reference 
, Adjusted for age, gender, country, and class; 95% CI in parentheses 
* p<O.OS 
74 
Survival and general characteristics 
TIle association between mortality and general characteristics is 
presented in table 2. Men had a significantly higher lllOltality rate; 
the median survival time for Ill.en was four months as compared to 
five lllonths for women (fig. 1). Classification as probable CJO and 
age at onset below 40 years as well as between 40 and 64 years 
were related to lower mortality rates (fig. 2). Residence in Germa-
ny was statistically significantly associated with a longer sUlvival 
of eight months as compared to four months for the other 
countries (p< 0.05, not in table). When analyzing the definite and 
probable patients separately, the differences between men and 
women and Germany versus other sites were not obsetved in 
definite CJO (ORR 1.09; 95% CI 0.90-1.32 and ORR 1.14: 95% CI 
0.94-1.38 respectively, not in table). Age at onset below 40 years 
and between 40 and 64 years remained significantly reduced in 
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Figure 1 - Survival 01 Creutzfeldt-Jakob patients by gender. 
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Figure 2 - Survival 01 Creulzleldt-Jakob patients by age at onset. 
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Table 3 - Survival in patients with Creuizleldt-Jakob disease 
Median 
(in Death rate ratio I 
Symptoms at onset Number months> 
crude adjusted' 
Rapid cognitive decline + 300 4 1.05 1.02 
228 4 <0.87-1.27) (0.85·1.24) 
Psychiatry + 114 4 0.84 0.99 
330 4 <0.69-1.02) 0.83·1.21) 
Sensory + 77 5 0.93 1.07 
432 4 <0.77-1.12) <0.88·1.29) 
Vertigo/Dizziness + 152 4 1.17 1.29'" 
363 4 <0.96·1.41) (1.07·1.56) 
Headache + 63 6 O.82~ 0.93 
440 4 0.67·0.99) <0.77-1.13) 
Seizures + 24 6 0.721. 0.66* 
478 4 <0.59·0.87) <0.55·0.80) 
Galt disturbances + 315 4 0.94 0.99 
203 4 <0.77-1.13) 0.81-1.93) 
Speech disturbances + 178 4 0.99 1.03 
338 4 (0.81-1.19) <0.85·1.25) 
Visual disturbances + 207 4 f .25'- 1.29* 
315 5 (1.03-1.51) (1.07·1.57) 
Forgetfulness + 310 4 1.12 1.06 
210 4 <0.92-1.35) <0.87-1. 28) 
I Adjusted for age, gender, country, and class; 95% cr In parentheses 
.. p<0.05 
76 
definite CJO (ORR 0.39; 95% CI 0.33-0.48 and ORR 0.81; 95% CI 
0.67-0.99 respectively, not in table), 
Survival and clinical features 
TIle association between mortality and the occurrence of clinical 
features is presented in tables 3 and 4 as cmde and as adjusted 
death rate ratios (ORR), After adjustment for gender, age, patho-
logical confirmation and countty, the presence of vertigo, visual 
disturbances and pseudobulbar signs at onset of disease were 
Prognosis 
Table 4 - Survival in patients with Creulzleldt-Jakob disease 
Signs at onset Number 
Median 
(in 
months) Death rate ratio' 
crude adjusted' 
Cerebellar + 240 4 0,89 0,96 
259 4 (0:14-1.08) (0,79-1.16) 
Visual/Oculomotor + 182 4 1.16 1.17 
326 4 (0,97-1,40 0,97-1.42) 
Extrapyramidal + 68 4 1.04 1.14 
437 4 (0,86,1.27) (0,94-1,38) 
Pyramidal + 47 4 1.18 1.17 
457 4 (0,97-1,43) (0,96-1.40 
Involuntary movements + 103 4 0,90 0,95 
404 4 0,74-1.09) (0,79-1.15) 
Myoclonus + 92 4 1.00 1.06 
421 4 (0.83-1.22) (0,87- 1.28) 
Pseudobulbar + 45 4 1.16 1.29* 
417 4 (0,96- 1.40 (1.06- 1.56) 
Neuromuscular wasting + 8 4 1.23* 0,97 
493 4 (1.02- 1.49) 
I Adjusted for age, gender, country, and class; 95% Ciin parentheses 
* p<O.05 
(0,79-1.17) 
both significantly associated with a reduced sUlvival (table 3), 111e 
presence of seizures at onset was after adjustment significantly 
associated with an increased survival. However, a significant in-
crease in DRR in definite patients was only found for visual dis-
Ulrbances (DRR 1.46; 95% CI 1.21-1.77, not in table) and a signifi-
cant decrease in DRR in definite patients for seizures (DRR 0.53j 
95% CI 0,44-0,65, not in table), 
111e concomitant occurrence of rapid cognitive decline, myoclo-
nus and typical EEG as described as the classical triad of CJD [4,6], 
was not significantly associated with a reduced survival as C0111-
pared to absence of these features (DRR 1.14; 95% CI 0,95-1.39; 
not in table), 111e concomitant occurrence of psychiatric, cerebel-
lar symptoms at onset of disease and the development of demen-
tia during the courSe as described in the new variant of GJD, was 
77 
Cfl4PTER 6 
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Table 5 - Survival in patients with Creutzfeldt·Jakob disease 
Median 
(in Death rate ratio' 
Number Genetic factors 
Aetiology 
Sporadic 
Genetic 
Iatrogenic 
PRNP mutation 
PRNP mutation 
Codon 200 
Codon 'other' 
+ 
+ 
+ 
554 
40 
12 
40 
313 
26 
313 
14 
313 
months) 
crude 
4 reference 
4 1.16 (0.96·1.41) 
7 0.59'(0.49·0.72) 
4 1.19(0.98·1.44) 
4 reference 
3 1.37'(1.13·1.66) 
4 reference 
5 0.91 (0.75·1.10) 
4 reference 
I Adjusted for age, gender, country, and class; 95% CI in parentheses 
* p<O.OS 
adjusted l 
reference 
1.23'(1.01·1.49) 
0.91 (0.76·1.11) 
1.20 (0.99·1.45) 
reference 
1.29'(1.07·1.57> 
reference 
1.05 (0.87·1.27> 
reference 
not significantly associated with an increased survival as com-
pared to absence of these features (DRR 0.82; 95% CI 0.68-1.01; 
not in table). 
Survival and genetic factors of the PRNP gene 
nle survival of aetiological subtypes as computed from the whole 
sample is shown in fig. 3. 111e association between mortality and 
genetic factors is presented in table 5. After adjustnlent for sex, 
age, pathological confirmation and countty, genetic cases were 
significantly associated with a reduced survival. 1he proportions 
of cases with or without mutations were computed only for 
patients with PRNP analysis available. Mutations of the PRNP gene 
were found in 40 patients; 26 patients had a mutation at codon 
200, six at codon 21 0, three at codon 178, one at codon 117 and 
four had an insertion. nle survival of patients with a PRNP muta-
tion was significantly different from sporadic CJD patients. 11,e 
tnedian survival time of patients with a mutation at codon 200 of 
PRNP gene was three months, for patients with a mutation at an-
Prognosis 
~ Genetic CJD , , , 0.9 1\ - - Sporadic CJD 
0.8 --I - - - - - -Iatrogenic CJD 
" 0.7 
\ 
I g> :~ 
0.6 +----\\-~ 
§ 0.5 +---+---' I 0.4 +----\~\~-T .. -,-
0.3 \'. 
\."" .. 
0.2 f----.--. ~ ,':'::..' " . - --
0.1 -,-~ \ ..... -- - - - -~ ..... _____ _ 
o 
o 5 10 15 20 25 30 35 
Duration of illness (months) 
Figure 3 - Survival of Creutzfeldt-Jakob patients by aetiological 
subtype 
other codon five months, as compared to four months for patients 
without a mutation. 11,e genotype of 355 sporadic, genetic and 
iatrogenic CJD patients were assessed for the polynlorphislll at 
codon 129 of the PRNP gene: 770/0 were homozygous for the 
methionine allele, 13% were heterozygous and 10% were 
homozygous for the valine allele. 11,e corresponding proportions 
were 7SOIo, 12% and 10% for sporadic CJD patients, 77%, 1SO/0 and 
5% for genetic CJD patients, and 50%, 33% and 17% for iatrogenic 
CJD patients, respectively. 
Table 6 (overleaf) shows the association between polymorphism 
at codon 129 of the PRNP gene and mortality overall and stratified 
by the presence of a mutation. \'7hen adjusted for sex, age, pathol-
ogical confirmation, and countty, carriers of at least one valine 
allele had a statistically significant lower mOltality in the overall 
analysis as well as in the analysis without a PRNP mutation. 
Among CJD patients without a mutation with CJD classified as 
definite a significantly prolonged survival was obsetved for car-
riers of the valine allele (DRR 0.63; 95% CI 0.52-0.77 for hetero-
zygotes and DRR 0.77; 95% CI 0.64-0.94 for homozygotes, not in 
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Table 6 - Survival in patients with Creulzfeldt-Jakob disease 
Median 
(in Death rate ratio 1 
Genetic factors Number months) 
crude adjusted! 
Overall 
Polymorphism codon 129 
MM 273 4 reference reference 
W 35 5 0.76'(0.63·0.93) 0.67'(0.55·0.81 ) 
MV 47 6 0.72'(0.59·0.87) 0.67'(0.55·0.81 ) 
No PRNP mutation 
Polymorphism codon 129 
MM 239 4 reference reference 
W 31 5 0.80'(0.66·0.97) 0.67'(0.55·0.81 ) 
MV 40 6 0.69'(0.57·0.83) 0.66'(0.54·0.79) 
PRNP mutation 
Polymorphism codon 129 
MM 30 4 reference reference 
W 2 4 0.28'(0.23·0.34) 0.37'(0.30·0.45) 
MV 7 6 0.88 (0.73·1.07) 0.84 (0.69·1.01) 
I Adjusted for age, gender, country, and class; 95% Ciln parentheses. 
Overall analysis also adjusted for mutation. 
* p<O.05 
table), Although numbers were small, among the genetic cases we 
also found a significant correlation between mOltality and 
polymorphism at codon 129 of the PRNP gene. 
Discussion 
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In our study of 606 CJD patients, female gender, early age at onset 
and classification as probable CJD were important prognostic fac-
tors. 11,e clinical feanu·es of CJD did not Influence sUlvival except 
for vertigo, visual disturbances and pseudobulbar signs, which 
were associated with a slight reduction in survival and seizures 
which were associted with an increased survival. In sporadic CJD 
PrognosIs 
the presence of at least one valine allele at codon 129 of the PRNP 
gene was a predictor of a relative increase in survival. 111e effects 
on survival related to early age at onset, visual dismrbances, sei-
zures, PRNP mutation and the genotype at codon 129 of the PRNP 
gene were confirmed in analysis of definite cases only. 
Regarding the validity of the data, the occurrence of clinical signs 
was assessed through examination of medical records. \Ve con-
sider it likely that neurological signs are accurately recorded par-
ticularly as CJO is usually a severe and rapidly progressive dis-
ease, although differences may exist between clinicians in differ-
ent centres. However, the assessment of symptoms recorded in 
the medical notes, depends on information from the patient's rela-
tives. Recall is liable to misclasslfication.29 Although this type of 
misclassification is expected to be random, we cannot exclude the 
possibility that recall bias has resulted in an apparent spurious 
association between symptoms and survival time. 
Age at onset below 40 years was associated with a significant in-
crease in sUlvival. 'The association between an early age at onset 
and long illness duration has been repolted in the literature for 
cases with inherited prion diseases7- 1O,17 and for cases with the 
new variant of (10. 11 •12 Our study Included 14 new variant CJO 
patients from the UK (among them two patients with age at onset 
above 40) and one from France. If these 15 patients are excluded 
frol11 the analysis, the median survival time for the age categOJY 
below 40 decreased from ten to seven months (adjusted ORR 0.45; 
95% CI 0.37-0.55; not in table). 11,is suggests that the prolonged 
sUlvival in early onset cases is predominantly but not fully 
explained by the patients with the new variant of CJO. Even if six 
iatrogenic cases with age at onset below 40 were excluded from 
the analysis, the age categOlY below 40 remained associated with 
a significantly prolonged survival (adjusted ORR 0.58; 95% CI 
0.48-0.70; not in table). However, the statistical power of this 
analysis was low given the small number of patients and the 
significant death rate ratio of 0.58 does not exclude the possibility 
that mortality lllay be reduced in younger patients in general. In 
general, younger subjects will have a higher life expectancy than 
older subjects. Furthermore, in relation to disease process it is 
possible that in younger persons subtle memory loss is recognized 
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and diagnosed at an earlier stage than in older patients, in whom 
subtle cognitive changes will be attributed to normal ageing. It has 
also been suggested that younger patients may have nIore relative 
brain reserve and have a higher clinical threshold for slowly 
progressive brain damage. lO Another possibility is that the 
expression of disease is different in younger patients, particularly 
in the new variant of CJD. 
We found a statistically significantly increased survival in probable 
cases, 111is is expected because 'long survivors' alive at censoring 
are per definition classified as probable. Misclassification could 
have occurred in patients who lack the subsequently neuropatho-
logical confirmation. We therefore stratified and verified our data 
for definite and probable CJD separately. Although all centres 
shared the same diagnostic protocol, there is evidence of 
heterogeneity among palticipating countries with regard to 
survival. 111e tiJue period between disease onset and diagnOSis 
was significantly longer in Germany than In other countries. 111is 
suggests that in Germany disease onset was defined more 
sensitively. Although a common protocol was used for diagnOSiS, 
the onset of disease was not strictly defined and personality 
disturbances at onset was more often repolted for German 
patients than for patients frol11 other sites. \Ve therefore perform-
ed our analysis for the German patients by date of clinical di-
agnosis as the definition for onset of disease. 
We found a statistically significant difference in the smvival of 
genetic patients in comparison with sporadic patients. In this 
study of incident cases of CJD single patients with different PRNP 
mutations have been identified and not multiple patients from 
individual pedigrees. 111ere may have been selective identification 
of genetic cases of CjD with a relatively short duration of illness. 
Various mutations of the PRNP gene have been associated with 
inherited prion diseases including familial CjD.Jo•31 In this study, 
the PRNP mutation was located in codon 200 in 26 of the 40 
patients with genetiC CJD, of whom 50% were from France. It has 
been suggested that the codon 200 mutation has less influence on 
the phenotypic expression than other PRNP mutations with age at 
onset and duration of illness almost indistinguishable from spo-
Prognosis 
radic CJD:~2,33 In contrast to these earlier findings, we found a 
significantly different, i.e. reduced, survival in carriers of the 
codon 200 mutation of the PRNP gene as compared to those 
without a mutation. The ShOlt sUlvival titue found in our study for 
genetic CJD patients could be ascribed to the high propoltion of 
codon 200 mutations and by the fact that in the analysis we adjust-
ed for sex, age and pathological confirmation, and took into 
account that not every patient was followed until death due to 
termination of the follow-up. 
nlere are a range clinico-pathological phenotypes in the human 
transmissible spongifonn encephalopathies or prion diseases in-
cluding: 'ataxic', 'Heidenhain', 'myoclonic', 'long duration', 'pan-
encephalopathic' and variants. 10,13,34+36 However, improved im-
munohistochemical and molecular genetic techniques suggest that 
the subclassification of human prion diseases needs to be re-
viewed. Beside the new variant of CJDl1 ,12, other forms of CJD 
have been postulated on molecular grounds and evidence of phe-
notypic variability.,,·38 
111e most striking clinical features of the new variant of CJD are 
psychiatric symptoms at onset and the long duration of dis-
ease. II ,l.2 In our study we did not find evidence to SUppOI1 an as-
sociation between psychiatric symptoms and increased sUlvival 
time in patients with classical CJD. 11,is suggests that the pro-
longed sUlvival in the new variant of CJD. which presents pre-
dOluinantiy with psychiatric symptoms, cannot be explained by a 
subgroup of patients with psychiatric presentation in patients 
with classical CJD. 111e identification of a subgroup of CJD cases 
with visual disturbance, associated with reduced stllvival is con-
sistent with the Heidenhain's variant of CJD, with occipital lobe 
pathology."'" 11,e occurrence of this type of CJD may be more 
frequent than reported, because visual symptoms and signs may 
be missed in patients with dementia. nle finding of the occur-
rence of seizures associated with a significantly increased sUlvival 
is in contrast what one should expect as seizures indicate severe 
involvement of the cortex. Furthermore, it Ill.ay sometimes be 
difficult to distinguish between involuntary jerky movements and 
epilepsy. Our data do not suggest any other clinical subtypes of 
CJD based on the concomitant occurrence of clinical features 
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except for the early onset patients with the new variant of CJD 
who have a longer surviva1.4,1l,12 
Considerable attention has been focused on the role of the com-
mon protein polymorphism at PRNP codon 129 in the pathogene-
sis of, and susceptibility to, pri~n diseases. TIle genotype fre-
quencies found for sporadic patients in our study are consistent 
with earlier sUlciies,14,IS,18 Among the inherited prion diseases the 
role of polymorphism at codon 129 of the PRNP gene in pheno-
typic expression of the disease is complex and depends on the 
type of mutation: among patients with a 144-bp Insertion a signifi-
cant correlation between an early age at onset with homozygosity 
at codon 129 of the PRNP gene has been reported. 17 Among pa-
tients with a codon 178 mutation those homozygous for the valine 
allele were associated with an early onset and longer duration9,1O; 
among patients with coelon 200 ulUtation no such correlation has 
been found. 7." Homozygosity at codon 129 of the PRNP gene 
either for the methionine or valine allele has been reported to 
predispose to sporadic or iatrogenic CJD. 15,16.19,30,39,40 In sporadic 
CJD the influence of the codon 129 genotype on clinical 
phenotype such as age at onset and duration of illness has been 
controversial. 18,19,41,41 
11,is study, the largest series of CJD patients with data on geno-
type at codon 129 of the PRNP gene, shows that among patients 
without a PRNP mutation heterozygosity and homozygosity for 
valine are associated with prolonged survival. Again, desrepancies 
may reflect differences in statistical analysis. In the present 
analysis we adjusted for censoring, age, sex, pathological confirm-
ation, and countly. Our finding is compatible with the view that 
the prion propagation and conversion into the abnormal isoform 
may therefore not only rely on identical copies of the prion pro-
tein but that also other genetic co-factors from the host may de-
termine the progression of the disease. 11,is finding highlights the 
importantinfluence the genotype at codon 129 of the PRNP gene 
has on both the pathophysiology and the prognosis of prion dis-
eases. 
Prognosis 
Conclusion 
n,is study does not suggest that the clinical features of classical 
CJD relate to stllvival. Gender, early age at onset and pathologi-
cal confirmation are important prognostic factors. Atnong CJD 
patients without a PRNP mutation homozygosity and heterozy-
gosity for the valine allele are associated with an increased 
sUlvival. n,is finding highlights the important influence of the 
genotype at codon 129 of the PRNP gene on the survival of prion 
diseases. Furthermore, this study indicates that the prolonged 
duration of illness in new variant CJD may not simply reflect the 
age at onset of disease Of the predominantly psychiatric present-
ation, providing further evidence that this form of CJD is clinically 
distinct from classical CJD. 
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Discussion 
I N TIlE PREVIOUS chapters we reported the EU collaborative studies on Creutzfeldt-Jakob disease (C]D) conducted in a three year period 1993 to 1995 and a re-analysis of case-control studies that was conducted in preparation of the prospective collaborative studies. In this chapter, first a 
brief overview will be given on the major findings of the 
incidence, case-control and survival analysis. Subsequently the 
methodological aspects of the three studies will be discussed 
separately. Finally, implications of the findings of the individual 
smdies will be addressed and directions for further research will 
be outlined. 
7.1 Findings 
In the European collaborative study the overall annual mortality 
rate in the three year period was 0.73 per million person years. l 
111is finding is consistent with earlier systematic surveys (table 1). 
111e incidence rates and age-specific-incidence rates were all rela-
tively similar in all participating countries. 111e IllOSt impOltant 
exception is the increased incidence in patients aged <39 years in 
the UK in particular in the year 1995 (0.14 per million person 
years). 2 In relation to aetiological subtypes, 90% of all cases were 
sporadic, 8"/0 genetic and 2% iatrogenic. With regard to risk factors 
studied the predominantly negative results of the re-analysis of 
three studies conducted in the period 1975-1984 re-emphasise the 
absence of a common risk factor in CJD patients in the period 
studied.25 In the case-control study of the collaborative EU smdies 
on risk factors we found significant evidence for familial aggrega-
tion of CJD as well as evidence for familial clustering of CJD with 
dementia due to other causes.26 A significantly increased risk of 
CJD was found for subjects exposed to domestic birds, leather 
products and fertilizer consisting of hoofs and horns. Of the 
dietary factors studied, the consumption of brain and raw meat 
were associated with an increased risk of CJD. No association 
could be shown between the risk of CJD and the consumption of 
beef, veal, lamb or milk. 
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Table 1 - Summary of nalional surveys 01 Creulzleldt·Jakob disease.2 
Annual mortalily rales (cases/year/million). 
Country Years Number Familial Mortality 
% cases/million 
Chile3.4 1955-1972 19 27 0.10 
1973-1977 16 0.31 
1978-1983 46 0.69 
Czechoslovakia5 1972-1986 46 22 0.66 
France2 1968-1977 178 6-9 0.34 
1978-1982 151 0.58 
England/VVales6-9 1964-1973 46 7 0.09 
1970-1979 158 4-6 0.31 
1980-1984 120 6 0.50 
1985-1989 0.47 
1990-1994 185 5 0.76 
ScotlandlWales9 ,1O 1980-1985 10 0.21 
1985-1989 15 0.60 
1990-1994 24 0.90 
United Kingdom 11 1990-1993 100 9' 0.67 
Hungaryl2 1960-1986 65 11 0.39 
[8rae1 13,14 1963-1972 23 4 1.07 
1963-1977 
Italyl5,16 1958-1971 32 8 0.05 
1972-1985 87 0 0.11 
Flnland 17. 18 1974-1984 30 20 0.57 
1979-1984 26 20 0.91 
1974-1989 44 25 
Japan'9 1975-1977 75 6 0.15 
United States2O-21 1973-1977 265 0.26 
1979 148 0.66 
1980 142 0.63 
1979-1990 0.90 
1986-1988 0.83 
Ubya23 1982-1986 0.48 
Austria24 1969-1985 79 0 0.18 
1986-1994 0.67 
1995 1.50 
.. Familia! were 9% of all cases and 13.4% of cases with DNA analysis. 
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In our study of survival of patients with CJD the median stllvival 
was four months. Female gender, early age at onset and a 
diagnosis of probable CJD were important prognostic factors. 27 
Most clinical features were not related to survival. In contrast to 
earlier findings, mortality tended to be increased in patients with 
PRNP mutations and/or a positive family history for CJD. Among 
patients without a PRNP mutation, 1ll01tality among carriers of at 
least one valine allele at codon 129 op the PRNP gene was signifi-
cantly lower. 
7.2 Methodological aspects 
nle epidemiologic sUlveillance of CJD is an important instnuuent 
for monitoring incidence, risk assessment and clinical course of 
human prion diseases in relation to animal spongiform encepha-
lopathies. However, when interpreting the findings it is crucial to 
review critically its weaknesses with regard to selection bias, in-
formation bias or confounding. 
Incidence study 
111e EU collaborative studies of CJD stalted In 1993 with the aim 
to provide comparative epidemiological data that would enable 
baseline epidemiological parameters to be established which will 
be cnIcial to the assessment of the risk of human prion diseases, 
in particular CJD in relation to animal spongifonu encephalo-
pathies. 
Case ascertainment 
Stllveillance of CJD is complicated by the rarity of the disease and 
the absence of a typical diagnostic test. To obtain meaningful 
results it is essential to achieve a high level of case ascertainment 
by systematic identification of incident cases. 28,29 In the EU 
collaborative studies case ascertainment has depended on two 
major mechanism: (J) direct referral from targeted professional 
groups: neurologists, neuropathologists and neurophysiologists 
and (2) death certificates in countries where they are accessible. 30 
CJD is usually a dramatic illness which generally occurs in the 6th 
and 7th decade of life, but patients with onset in early adolescen-
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ce and late senescence have been repOlted.31 -34 111e median survi-
val from first symptoms to death is approximately four months but 
may be as long as 13 years.3S-37 In countries with a developed 
medical system it is extremely unlikely that patients who become 
totally dependent will not be admitted to the hospital and subse-
quently referred to a neurologist. However the referral of CJD 
cases to a national regislIY depends fully on the cooperation of 
neurologists and other professional groups as well as the coop-
eration of relatives of the patients. In order to identify a high pro-
portion of cases, including arypical variants, the referral of any 
suspect case is mandatory. 38 
Diagnosis 
Diagnostic classification of cases in definite and probable CJD is 
standardized in the collaborative European study.39 However we 
did find heterogeneity among countries regarding post mOl1em 
rates varying from 41% to 100%. Practical difficulties have risen in 
obtaining autopsies in CJD because of potential risks to personnel 
in pathology departments despite the availabiliry of guidelines to 
minimize potential risks during postlnortems.40 Twenty-three pa-
tients undetwent brain biopsies; 10 also had a post mortem. Light 
microscopic examination of the biopsy specimens showed spongi-
form change in 8 (80%) of the autopsy verified cases. Criteria for 
the diagnosis of CJD were first proposed in 1979 but have been 
adapted according to acquired scientific knowledge about iatro-
genic CJD and genetic form of prlon diseases. 2o•39 111e EEG is 
crucial to distinguish probable from possible cases where there is 
no pathological confirmation of the diagnosis. In SOBle cases of 
CJD, no EEG is carried out and in others only a single tracing is 
obtained early in the course of the illness. 111e chances of 
obtaining a characteristic record are enhanced if serial recordings 
are carried out. A major problem with the use of EEG for the 
diagnosis of CJD is that there are no standardised established EEG 
criteria . .38 An EEG with generalised periodic sharp wave activity at 
0.6-2 Hz supports the clinical diagnosis of CJD. Recently a sens-
itivity of 67% and specificity of 86% was computed for the rypical 
EEG tracing in CJD.41 Misclassification of EEGs may occur because 
of variation in EEG reports by clinicians. 111erefore it is important 
for the national registries to build up expertise in reviewing EEG 
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of all referred cases.'8 A high degree of case ascertainment is 
crucially dependent on obtaining a high postmortem rate of all 
suspect cases. In this prospective study cases were included ac-
cording to the diagnostic status on May 1st 1996. TIle case clas-
sification upon inclusion may change according to the availabiHry 
of information especially on neuropathological information. 
Atypical cases, such as those with a stroke-like presentation or a 
long duration of illness, may not be clinically recognized as CJD 
and identification may only be possible through neuro-
pathological examination.42 
In the descriptive epidemiology of CJD mortaliry figures are often 
used to compute the annual and age-specific mortality rate per 
million person years (table 1). For the collaborative study on CJD 
we computed both incidence for cases with onset of illness in the 
three year time period 1993 to 1995 as well as mortaliry for cases 
with date of death in the three year period 1993 to 1995.' 
Difference between those two figures may have occurred due to 
the fact that in the first year of the prospective study mortaliry 
figures may be underestimated because emphasis in the new 
established registries may have been focused on incidence rather 
than mortaliry. Also, at the end of the three year period mortaliry 
data may underestimate cases with an atypical long duration. 
Despite these considerations the difference between the incidence 
and mortality is in most cases almost negligible because of the 
short median duration of illness of four months. 
Studies of genetic forms of prion diseases have established 
marked phenorype variation in the clinical and pathological fea-
tures of CJD.43•44 A proportion of these cases do not fulfll current 
diagnostic criteria for CJD. In the UK systematic use of DNA 
analysis in CJD has demonstrated that about 13.4% of cases with 
DNA analysis are associated with PRNP gene mutations. ll Approx-
imately one third of these cases have no evident family history of 
CJD. TIle low percentage of genetic cases of eight per cent in the 
coliaborative study is likely to be expiained by the different per-
centages of DNA analysis performed in the participating countries 
varying from 100% of cases analyzed in Slovakia, 80% in 
Germany, 78% in France, and 60% in Italy compared to 58"Al or 
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less in other countries. Furthermore, the figure of eight per cent 
may be slightly underestimated as it remains possible that not all 
novel mutations within the PRNP open reading frame CORF), nor 
PRNP mutations outside the ORF, may have been detected. ll 
Risk factors 
Case-control studies have been carried out in the past in the 
United States, United Kingdom, Israel and Japan to assess poten-
tial risk factors for CJD."·51 Due to the low frequency of the dis-
ease all five studies included only small numbers of patients. 111e 
few positive associations from these shlciies were llmhmlly incon-
sistent and even the fe-analysis of three case-control studies46-50, 
comprising patients diagnosed with CJD according to the criteria 
of Masters et aI., lacked statistical power to provide significant 
positive associations for rare exposures, which is reflected in the 
width of the 95% confidence intervals. 2S However, the joint 
registries of the collaborative studies which share common 
methodologies, induded 405 CJD cases and provided sufficient 
statistical power to study a number of putative risk factors for 
CJD.26 
Selection bias may have occurred for several reasons. First 
through non response in cases and controls in the different coun-
tries. TIle percentage of cases from the national registries included 
in the case-control studies varies from 39% to 88<'10 11,ese differ-
ences may be caused by the major practical and geographic 
problem to conduct the studies of CJD on a nationwide basis be-
cause of its rarity and random occurrence. The vital status of cases 
at time of interview may have influenced the selection of cases 
into the case-control study. Especially for cases ascertained from 
neuropathologists and death certificates where there had been a 
prolonged delay in obtaining hospital notes 01' other conformation 
of the diagnosis, there might have been caution to approach rela-
tives. TIley were therefore excluded from the case-control study. 
Controls were selected for each case using the following criteria: 
sex and age C +/- 5 years) matched, inpatient in the same hospital 
as the case, and excluding patients with a neurodegenerative dis-
ease. TIle response rate for controls is not known, but is generally 
lower than in cases. In general, findings may have been biased if 
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the response rate in cases and/or controls was associated to the 
risk factors studied like geographical distribution. 
111e use of hospital controls may have introduced selection bias in 
that exposure frequencies to surgery, Iuedical disorders and or 
medical treatment may not be representative for the general 
population. 111e preference for neurological controls with exclu-
sion of neurodegenerative disorders may have led to a potentially 
over-representation of common risk factors and therefore the as-
sociation found may have been an underestimation of the real 
association. 111e validity of the case-control study may have been 
compromised as only one study centre selected control series 
from the general population. 
Information bias has inevitably occurred as the information on 
possible risk factors for CJD cases was obtained through a stnlc-
lured interview with a surrogate informant, mainly a next of kin. 
To achieve synuuetrical data collection, information on risk factors 
for the control subject was also obtained from a surrogate infor-
mant. In each case-control pair relatives of an identical degree 
were interviewed whenever possible. However in some instances 
control subjects were interviewed in person. 'I11is may have 
introduced a systematical difference between cases and controls 
that could have affected the validity of the findings. For all risk 
factors, the data were analyzed including only patients and 
matched controls for whom the data were obtained from a next of 
kin. 
Another form of information bias may have been recall bias, as 
relatives of CJD cases are more likely to remember putative expo-
sures in the past than informants of controls. Important determi-
nants for this form of recall bias are time between onset of C.JD 
and the interview and the vital status of the patient at time of the 
interview. Stratified analysis for these determinants did not change 
the results. As the incubation period in human prion diseases may 
be e:A'1remely long with a mean incubation period of 13 years in 
human growth hormone recipients and a range of incubation pe-
riods from 5 to over 30 years in Kuru, risk factors studied must 
include potential exposure in early childhood.52 In general, infor-
mation obtained from decades in the past may in itself introduce 
recall bias. 
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Another potential source of information bias which may have oc-
curred non-differentially is the awareness of relatives of the hy-
pothesis tested. Since the outbreak of BSE in the UK in 1986, there 
has been great public and media interest in a possible link be-
tween BSE and CJD.53 As the collaborative studies were carried 
out in 1993 to 1995, so before the new variant CJD became front 
page news in Europe, it seems reasonable to assume that bias has 
mainly afflicted dIe UK up until 1995, given the media attention in 
the UK. However, given the size of the BSE epidemic In the UK 
compared to other European countries, one may argue that the 
exposure frequencies in the UK may have differed significantly 
froln those at the European mainland. Also, the perception of the 
interviewer may have been influenced by the awareness of pos-
sible causes, In this respect it is important to note that interviewers 
were not blind to disease staU1S of the subject interviewed. 
We performed stratified analyses for definite and probable CJD 
separately. In the case-control study the risk estimates for putative 
risk factors from the stratified analysis did not statistically signifi-
cantly differ form the unstratified analysis. 
Confounding - Although putative confounders as age, sex and 
study centre were effectively controlled for, there may be several 
yet unknown risk factors Including genetic factors not controlled 
for in the analysis. At present it is impossible to exclude this 
source of bias. 
Survival 
Survival analysis was carried out with incident cases from the reg-
istries with their onset of disease in the three year period of 1993 
to 1995. Duration of illness was defined as the period from first 
symptoms to death or to censoring date at May 31 1996.27 In con-
trast to earlier studies, we took into account in the analysis that 
not every patient was followed until death due to termination of 
the follow-up of patients on May 31 1996. 
Selection 
111e majority of cases from the registries were included in the sur-
vival analysis. Patients lacking basic clinical information on clini-
cal course as date of birth, date of first symptoms and date of 
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death had to be excluded. Similar to the possibIlities of bias in the 
incidence studies bias may have occurred in the ascertainment of 
cases. For instance there may have been selective identification of 
genetic cases of C]D with a reiatively short duration of illness. 
Information 
Data on the occurrence of clinical signs were assessed through 
examination of medical records. Neurological signs were assumed 
to be recorded accurately in the medical records due to the sever-
ity and rapid progression of the disease although differences may 
exist between clinicians from different countries. 1be assessments 
of symptoms recorded in the medical notes, depends on informa-
tion from the patient's relatives. Although this type of misclassifi-
cation is expected to be ranciOlll, we cannot exclude that recall 
has caused an effect between occurrence of symptoms and sur-
vival time. In the survival analysis probable caSes had a signifi-
cantly longer survival as compared to definite cases. 111i5 may be 
explained by the misclassification of other neuroiogical disorders 
as probable C]D. In the analyses we therefore stratified and veri-
fied our data for definite and probable cases. Although all centres 
shared the same diagnostic protocol, there is evidence for hetero-
geneity among participating countries with regard to survival. 'The 
onset of disease was not strictly defined and personality distur-
bances at onset were more often reported for German patients. 
Confounding 
We adjusted for possible confounders including gender, age, 
classification as probable and countty of residence. Again, there 
may be yet unknown predictors including genetic factors not ad-
justed for. 
7.3 Implications 
Incidence 
Variation in measurements 
'The mortality of the prospective collaborative snldy in the three 
year period of 1993 to 1995 was 0.73 per million person years.! 
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Earlier systematic surveys consistently reported a mOltality of 
around 0.5 cases pel' million per annum (table 1). Most studies 
were done on a nationwide basis and cases were identified retro-
spectively through death certificates, neuropathology reports Of 
medical records. However, higher mortality figures were oc-
casionally repOlted for a number of countries for localized areas 
as Slovakia and Libyan born Israelis which could eventually be 
explained by a high frequency of mutations in the PRNP gene.' 
Surveillance in small countries leads to an unstable incidence/ 
mOltality estimate. Variation in incidence figures may occur by 
sampling error if inddence/mol1ality figures for a rare disease 
such as CJD are based on a small number of cases in a restricted 
area over a limited period of time. TIl is could explain the fluctu-
ation of the annual mortality rate of in particular Austria and the 
Netherlands in the period studied. I•24 In the UK the geographical 
distribution of C,JD over the past 20 years showed no evidence of 
spatio-temporal aggregation of CJD despite the occurrence of 
local areas of relatively high incidence over short periods.)O 
Age-specific incidence curve 
TI,e sharp decline of the incidence of C]D in all countries of the 
collaborative studies in the age group above 80 years is in contrast 
with observations in other neurodegenerative disorders such as 
Alzheimer's disease. 1,S1 111is may reflect a more difficult ascertain-
ment of CJD in the older age-groups. In contrast to what should 
be expected based on this hypothesis, this decline is also seen in 
the UK despite their higher asceitainment in the elderly since 
1990.9 An alternative explanation may be that the genetic suscept-
Ibility determines the shape of the curve. Expression of the prion 
protein gene may be age dependent and highest at relatively early 
age and low at high age. 
Despite the relatively siInilar overall incidence rates for the par-
ticipating countries in the collaborative studies, there was a 
marked, approximately fourfold, increase in the age-specific 
incidence in the year 1995 for cases aged < 39 year in the UK 
compared to the other European countries,] A possible explana-
tion of this increased incidence among young patients may be a 
better ascertainment in the younger age-groups by analogy of the 
Increased overall incidence of CJD In the UK in the 1990s due to 
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improved asceltainment of CJD in the elderly.9 However, this 
group comprises 14 cases with the new variant of CJD.55 The 
occurrence of 14 cases with new variant CJD emerging in the UK 
in a relatively short time period with a distinctly different clinico-
pathological presentation in a for classical C]O unusual age-group 
and in the absence of encoding mutations of the PRNP gene 
associated to C]O raised the question wether this was a new form 
of C]O in the UK.55.56 The strikingly common neuropathological 
picture of these cases Indicates infection with a conmlon strain of 
the causative agent which shows similarity with the pathology 
seen In scrapie in sheep.57 At least 20 different strains of scrapie 
prions can be distinguished in mouse models inoculated with 
scrapie brain on the basis of disease-incubation period and neuro-
pathological profile. 111e most obvious explanation for this new 
type of CJO emerging in the UK Is a link with BSE. BSE has most 
likely been caused by feeding cows scrapie infected brains. 
Recently, evidence In support of a causal link between BSE and a 
new variant C]O Is provided by experimental transmission of BSE 
to macaques, revealing neuropathological siJnilarity to new variant 
CJD. Furthermore, biomolecular studies provided evidence of a 
distinct strain of the causative agent associated to new variant CJD 
that is distinctly different from two strains of the causative agent in 
classical C]O and one strain in iatrogenic CJO. The similarity on 
Western blots between the prion protein of new variant C]O and 
ESE was striking. 58 
The exposure of the general population to the BSE agent through 
consumption of meat products containing high titres of BSE prl-
ons, Is likely to have been greatest in the eighties which indicates 
incubation periods of between five to ten years. This is 
compatible with a relatively shOlt incubation period as compared 
to a mean incubation period of 13 years In human growth hor-
mone recipients and a range of 5 to 30 years in Kunt, because in 
these cases there is no so-called species barrier.59,60 This may 
Indicate a low threshold of the species barrier between cattle and 
humans for the ESE prions. However, we are presumably in a 
very early phase of a new variant 'epidemic' as the cases that have 
been identified so far represent minimum incubation periods and 
it is most likely that the mean/median latency time In patients 
with new variant CJD is to increase due to the cases still to 
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develop.6! TIle question emerges why this new variant of C]D 
afflicts particularly young patients. One reason could be that 
younger age groups are more susceptible because of the age-
dependent expression of the prion protein gene. ll1e similarity in 
genetic make-up of new variant CJD cases, coding luethionine/ 
methionine for the polymorphism at codon 129 of the PRNP gene 
supports this hypothesis. Another possible explanation may be the 
luisdiagnosis of the new variant in the older age-groups, especial-
ly in those in which dementia is more cOIllIllan,54 Finally, the ab-
sence of the new variant in the older age-group lllay be associated 
to an aged related exposure of the causative agent in relation to 
food consumption patterns. However, there is no obvious reason 
to believe why the consumption of with BSE prions contaminated 
meat products was restricted to the younger age groups alone 
unless through the consumption of 'modern' food products such 
as hamburgers that are not consumed by elderly. AB the first 
patient with new variant C]D aged fifty has been identified [RG 
Will, personal communicatlont it remains to be seen wether new 
cases of new variant C]D will afflict all age-groups equally, if they 
occur at all. 
Risk factors 
Case to case transmission of CJD has been proven to occur 
through accidental iatrogenic contamination via neurosurgical 
procedures, EEG electrode implantations, corneal transplantation 
and human and gonadotrophin hormone.59 Non iatrogenic case-to 
case transmission remains speculative. Two major objections have 
been raised to reject case to case transmission as a mechanism of 
acquiring sporadic CJD2. First, examples of contact between cases 
are rare and the risk of acquiring CJD appears not to be greater in 
highly exposed individuals as spouses, friends, nurses and physi-
cians. Iatrogenic transmission was rare in the re-analysis of case-
control snldies conducted in the period 1975 to 1984." Also, this 
re-analysis failed to show statistically significant evidence for 
transmission frOIll cattle to humans. However, the data on the 
presence of prion disorders in patients or animals to which pa-
tients were exposed were not available in the time period studied. 
In the light of the new variantCJD and the possible link with BSE, 
the prospective case-control study of the collaborative smdies 
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conducted in 1993 to 1995 may yield impOltant clues on the risk 
assessment of CJD in relation to BSE." TIle availability of Infor-
mation on genetic factors as mutation of the PRNP gene and 
polymorphism at codon 129 of the PRNP gene has made separate 
analysis possible of genetic and sporadic cases. 
Genetic factors 
TI,e finding of familial aggregation of CJD as a statistically signifi-
cant risk factor for CJD is what one would expect as various 
dominant mutations in the PRNP gene on chromosome 20 have 
been linked with human prion diseases including particular famil-
ial CJD.'3.44 In the case-control snldy of the collaborative snldies 
only a proportion of the genetic CJD cases with a PRNP mutation 
were included in the case-control snldy. It is known that a family 
hlstOlY was not ascertained in 30 to 60 per cent of the cases har-
bouring PRNP mutations."·62 So the odds ratio of 12.0 found for 
familial aggregation of CJD may underestimate the tnle associa-
tion. The analysis further showed a significant association be-
tween CJD and family histolY of dementia due to other causes 
than CJD. In a number of patients with a familial form of de-
mentia, PRNP mutations have been found and the familial 
segregation of CJD and dementia may therefore be related to 
PRNP ulUtations segregating In these families.63 However, other 
genetic factors (such as the apolipoprotein E gene, which is asso-
ciated with both the risk of CJD and Alzheimer's disease) or non-
genetic factors may underlie the relationships.64.66 
Iatrogenic transmission 
In agreement with earlier findings, iatrogenic CJD appears to be 
rare as no association of CJD related to medical histolY could be 
shown in this large population-based sample of CJD patients.26 
However, there are two reasons to interpret these findings with 
caution. First, the referral of iatrogenic cases to the national sur-
veillances may have varied among countries and may fl1lthermore 
have been excluded from the case-control study as the source of 
accidental contamination for these cases, such as human pituitalY 
growth hormone, corneal graft or dura mater graft, was known. 
Furthermore, the findings should be interpreted with caution 
because of the limited validity of our snldy due to the use of 
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hospital controls. As mentioned earlier, the association found of 
CJD to surgelY, blood transfusion, and lumbar punculre can 
largely be explained by the use of hospital controls. Further 
studies with population-based controls and precise definition of 
potential incubation periods should be carried out in the future. 
Link between qD and BSE witWn Europe 
There was no significant evidence in the case-control study of 
transmission of CJD from cattle to humans. With regard to the oc-
cupational exposure to patients or patient material, there was a 
non significant increase in risk of CJD for subjects employed as 
health professionais. With regard to the consumption of meat or 
meat products, the consumption of brain and raw meat was as-
sociated with an increased risk of CJD. However the absence of a 
dose response relation between the consumption of raw meat and 
the risk of CJD makes a dose-effect relation less likely. In the light 
of a possible link between CJD and BSE, it is interesting to con-
sider the PRNP codon 129 genotype of the CJD cases with raw 
Bleat exposure in analogy to the homozygosity for the methionine 
allele among the new variant CJD cases, 55 
As brain tissue, spinal cord and eyes are expected to contain the 
highest concentration of prions, the increased risk of CJD with the 
consumption of brains, in particular those from cows, would sup-
port the hypothesis of a link between CJD and BSE. However, the 
analysis showed an increased risk of qD for the consumption of 
pig brains as compared to cow brains, which argues against a 
causal relationship as the probability of prion disease is much 
higher in cows. No evidence was found for an increased risk of 
CJD associated with (occupational) exposure to cattle or sheep 
(products) or with the consumption of beef, veal or lamb. TIle 
negative results of QUI' analysis are important in the light of public 
health to re-emphasise that at present the case-control study of the 
EU collaborative studies do not provide evidence for a link be-
tween BSE and CJD. However these findings should be interpret-
ed with. caution as the study includes patients with onset of 
disease before or in 1995. So far the number of new variant CJD 
cases included in the case-control study was small and we will 
have to await future studies to see wether consumption of beef, 
veal or lamb may increase the risk of new variant CJD. 
7.4 
Discussion 
Survival 
ll1e survival analysis does not suggest that clinical feanlfes of 
classical CJD are related to survival except the new variant of 
CJD.27 There is a significant difference in survival between men 
and women. 111is may be related to an earlier diagnosis of the 
disease in men. Also, mortality in the general population is higher 
in tHen than in women. TIle prolonged duration of illness in new 
variant CJD does not simply reflect the age at onset of disease or 
the predominantly psychiatric presentation providing further evi-
dence that this form of CJD is clinically distinct from classical CJD. 
The collaborative studies provide the largest data set ever as-
sembled with information on the genotype of the polymorphism 
at codon 129 of the PRNP gene. 111e study confirms the role of 
genetic factors in the pathophysIology and the prognosis in prion 
disease, in particular in sporadic CJD. 111e recent findings of foUl' 
distinctly different strains in classic, new variant CJD and iatro-
genic CJD illustrates the impOltance of the genotype of PRNP 
gene in the host for the monomorphic phenotypic expression of 
the different prion strains in CJD." 
Directions for further research 
Continuing the surveillances of CJD in Europe 
Continuation of the EU collaborative studies on CJD in Europe 
will provide important comparative epidemiological data to mon-
itor any change in the incidence of CJD, and in particular new 
variant CJD, attributed to BSE. With the identification of the new 
variant of CJD in the UK it was notewol1hy to have comparative 
data available that showed that in other European countries with 
different incidence figures of BSE, in the same period in particular 
in the year 1995, no increase has been obsetved in the incidence 
of CJD in young patients. In relation to the hypothetical risk of 
BSE and other animal prion diseases for humans an atypical form 
of prion disease in humans was considered possible, by analogy 
to the atypical clinical presentation of the first human growth 
hormone recipient.67..68 Indeed, all cases with the new variant that 
have been linked to CJD presented with aspecific psychiatric 
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symptoms in an unusual age group for classical C]D,S5 111e 
question emerges wether we have to adapt the ascertainment to 
this new knowledge and extend the targeted professional groups 
to psychiatrists and paediatrics, which will inevitably result in 
I1l30Y more referrals of suspected cases who in the end will not be 
related to C]D. On current evidence a clinical diagnosis of new 
variant C]D cannot be made during the psychiatric phase of the 
illness and diagnosing of these cases depends on the evolution of 
neurological signs.55 All cases with new variant GJD were prompt-
ly referred to a neurologist within eight weeks after the neurologic 
symptoms had developed [R.G. Will, personal conununicatlonl. 
Crucial for the ascertairunent of C]D, especially with regard to 
atypical cases which are not clinically diagnosed with C]D, will be 
the maintenance of a high level of post mortem rates. 
Improvement of diagnosis 
l1le accuracy of clinical diagnosis is over 95% in cases with a typi-
cal presentation and a characteristic EEG,38 However neuropa-
thological confirmation of the diagnosis remains an important 
component of the surveillance as a small proportion of cases may 
not be clinically suspected of CJD or do not undergo (serial) EEG 
recordings. In Ule atypical clinical course of new variant CJD it is 
important to critically review the diagnostic criteria. Some consid-
erations to improve the diagnosis and case classification are 
briefly discussed. 
Adaptation of diagnostic criteria currently used in the collaborative 
sntdies is mandatory. However) the majority of the 14 new variant 
cases in the UK were notified through the normal surveillance 
system and only one of these cases was identified solely by post 
mol1em examination. 55 Further studies have to evaluate wether 
the clinical features of the 14 new variant patients represent the 
uniform phenotypic expression of new variant CJD in humans 
linked with BSE. It will be important to perform serial EEG 
recordings to enhance the chances of obtaining a characteristic 
recording of the EEG and to establish EEG criteria for the 
diagnosis of CJD. 
Discussion 
Brain biopsies as a diagnostic investigation in CJD remain contro-
versial as they cany a notable morbidity and may be non infonu-
ative as an unaffected region of the brain is obtained.'" Especially 
in young cases biopsies are occasionally perfonuecl if treatable 
alternatives of CJD are seriously considered. However, the pre-
dictive value of a negative finding at pathology is low. 
Recently a diagnostic test of CJD has been reported based on im-
munoassay of 14-3-3 protein in the cerebrospinal fluicl.70 111e test 
rapidly detects neuronal loss and false positive results have been 
reported in herpes encephalitis and carcinomatous meningitis 
with a primary small-cell carcinoma of the lung.70,71 It will be cnl-
cial to derive large patient-series for the development of tests for 
which pooling of patients from different centres is necessary. Fu-
ture research has to determine the specificity of the test in differ-
ent stages of the disease and the specificity in animal spongifonn 
encephalopathies as BSE and scrapie. At present there is no evi-
dence suggesting an interaction of these proteins in the patho-
physiology of prion diseases. 
Collinge et al. recently repolted for classical, iatrogenic, and new 
variant CJD specific patterns of protease-resistant prion protein on 
Western blot analysis. s8 11,ey showed that this marker could be 
used to aid differential diagnosis on brain and tonsil biopsy 
samples as the prion protein is widely expressed outside the 
central nervous system in the lymphoreticular system.72 
If new variant CJD is caused by BSE, early diagnostic markers 
sllch as the immunoassay of 14-3-3 protein in the cerebrospinal 
fluid and the protease-resistant PrP in tonsillar tissue will allow 
early clinical diagnosis of (new variant) CJD. However, large 
prospective studies are necessalY to evaluate the clinical 
relevance of these tests. 11,e ongoing collaborative studies of CJD 
will provide patient tissue to enable research in developing a 
diagnostic test ante mortem. 
Exposure 
An imponant issue to tackle in future research is the exposure 
assessment. Putative modes of transmission from cow to man in-
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eludes nutrition, medication and animal exposure. 111e opera lisa-
tion to assess exposure to BSE infected tissue is particulaty diffi-
cult in the first above-mentioned fields. With regard to nutrition, 
mechanically derived meat may hypothetically be infected be-
cause of contact with brain and/or spinal cord tissue. Up until 
now it has been impossible to trace the products of ESE cows in 
food products and medication. 111e issue of exposure will be cnl-
cial in future epidemiological research. 
Gene susceptibility 
Animal studies as well as the EU collaborative studies suggest that 
genetic factors other than PRNP genes must be implicated. It will 
be crucial to find these genes. From a public health point of view 
this will enable 'lls to detect subgroups of people (or animals) 
genetically susceptible for the disease. From a scientific point of 
view, identification of these genes will give new insight in the 
pathogenesis of CJD through its gene product (protein). From a 
clinical point of view these genes may eventually lead to the 
development of new diagnostic tests and perhaps subsequently 
lead to a therapy. 
Discussion 
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CHAPTER 
Summary 

Summary 
HAPTER 1 gives a brief ovelview of various issues of the 
collaborative European studies on incidence, risk factors 
and survival of Creutzfeldt-Jakob disease (CJD) described 
in this thesis. In historical context, the epidemiological sur-
veillance of CJD conducted by Professor WB Matthews in 
the UK throughout the seventies and early eighties served as a 
basis for the collaborative studies conducted from 1993 to 1995. 
n,e collaborative studies were possible through funding from the 
European Community for coordination of national CJD sUlveil-
lance programmes to evaluate any changes in the pattern of CJD 
that might be attributable to BSE. 
Chapter 2 reviews the evidence for risk factors of Creutzfeldt-
Jakob disease by pooling and re-analyzing the raw data of three 
case-control studies, conducted in the United States, Japan and 
United Kingdom during the seventies and early eighties. Despite 
the difference in methodology between the individual studies, 
they shared similar diagnostic criteria as described by Masters et 
at. n,e pooled data set comprised a total of 178 cases and 333 
controls. n,e risk of CJD was statistically significantly increased 
for subjects with a family histOlY of CJD. Further, there was a sig-
nificant association between the risk of CJD and a histOlY of psy-
chotic disease. Although not significantly increased, there was an 
elevated risk of CJD for subjects employed as health professionals 
and subjects ever exposed to cows and sheep. No association 
could be shown with organ meat consumption including brain. 
OUf re-analysis did not support a number of previously reported 
associations. 111e negative results of this re-analysis re-emphasise 
the absence of a common risk factor in all Creutzfeldt-Jakob pa-
tients. 
Chapter 3 examines in detail the shared methodologies and gen-
eral design of the collaborative studies on incidence, risk factors 
and survival of CJD. First, the common diagnostic criteria applied 
to all CJD cases included in the collaborative studies are de-
scribed. Subsequently, case ascertainment in the various partici-
pating countries, i.e. Belgium, France, Germany, Italy, the Nether-
lands and the UK, are addressed with emphasis on the design of 
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the register in the Netherlands and Belgium. Also the process of 
data collection, data processing and at last the statistical analysis 
are outlined for the three collaborative studies. 
Chapter 4 presents the descriptive epidemiology of the collabo-
rative studies on CJD in Europe. In the three year time period 
from 1993 to 1995 570 definite or probable cases of C./D were 
identified in the collaborative studies with an overall annual mor-
tality rate of 0.73 cases per million person years. Both incidence 
and 11lortality figures are described which are approximately 
siInilar due to the shOlt mean duration of illness. 111e mortality 
rates for CJD were similar in all participating countries despite 
variations in post mortem rates, and age specific tllortality rates 
were also relatively consistent, with the exception of an increased 
mortality of C./D in patients aged < 39 years in the UK. In relation 
to the aetiological subtypes of C./D, 90% of cases were sporadic, 
SOlo genetic and 2% iatrogenic. 111ese incidence data establish 
baseline epidemiological parameters for C./D in participating 
European countries, which Illay be important in the assessment of 
any future change in the characteristics of CJD as a result of the 
epidemic of BSE. 
In chapter 5 the results and the analysis of the collaborative 
European study on risk factors for Creutzfeldt-Jakob disease are 
described. Four hundred and five patients with definite or pro-
bable C./D derived from the population-based studies conducted 
in the period from 1993 to 1995 were included in the case-control 
study and compared to 405 hospital controls. We found significant 
evidence for familial aggregation of C./D as well as familial aggre-
gation of C./D with dementia due to other causes than C./D. A sig-
nificant increased risk of C./D was found for subjects exposed to 
domestic birds, leather products and fertilizer consisting of hoofs 
and horns. Of the dietary factors studied, the consumption of 
brain and raw meat was associated with an increased risk of C.JD. 
In the period studied, no association collid be shown between the 
risk of CJD and to the consumption of beef, veal, lamb, cheese or 
milk. 
Summary 
Chapter 6 describes the prognosis of patients with CJD. Clinical 
characteristics associated with survival may yield important clues 
for the definition of clinical subgroups in CJD including new vari-
ant CJD. Six hundred and six cases with definite or probable CJD 
were derived from the collaborative European studies on CJD and 
were included in the survival analysis. Duration of illness was 
defined from first symptoms to death or censoring date (May 31, 
1996). 111e overall mean survival of CJD patients was six months. 
Gender, early age at onset and a diagnosis as probable CJD were 
important prognostic factors. Most clinical findings were not 
related to survival. In contrast to earlier findings, mortality tended 
to be significantly increased in patients with a PRNP mutation 
and/or a positive family histOlY of CJD. Among patients without a 
PRNP carriers of at least one valine allele were associated with a 
significantly erduced mortality. 111e findings do not provide evi-
dence for a clinical subgroup of CJD that relates to survival except 
for new variant CJD but do highlight the influence of genetic 
factors in the pathophysiology and prognosis of prion diseases. 
Chapter 7 gives a brief ovelview of the major findings of the col-
laborative studies on incidence, risk factors and survival of CJD. 
Subsequently, the methodological aspects of the three studies are 
discussed separately. Finally the implications of the findings of the 
individual studies are addressed and we tried to assess their 
design and analysis. TIle chapter ends with recommendations for 
future research, i.e. to continue the epidemiological surveillance 
of CJD in Europe for many years in order to assess the risk of BSE 
for humans in relation to the potentially long incubation period of 
the causative agent. 
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Samenvattlng 
H OOFDSTUK 1 van dit proefschrift geeft een kort overzicht van de ondetwerpen die zijn bestudeerd in een gemeen-schappelijke Europese studie naar incidentie, risicofacto-ren en prognose van de zlekte van Creutzfeldt-Jakob. Als voorbeeld voor deze gemeenschappelijke Europese 
snldie diende de epidemiologlsche snldle naar de ziekte van 
Creutzfeldt-Jakob die in de jaren zevenUg en het begin van de 
jaren tachtig door professor Matthews in Engeland en Wales werd 
uitgevoerd. De studies werden lllogelijk gemaakt door subsidie 
die de Europese Unie In 1993 verleende voor cotirdinatie van na-
tionale 'surveillances' in Belgie, Frankrijk, Duitsland, Italie, Neder-
land, Slowakije en het Verenigd Koninkrijk, om eventuele veran-
deringen in het v66rkomen van de ziekte van Creutzfeldt-Jakob 
op te sporen die mogeJijk zijn gerelateerd aan de 'dolle-koelen-
ziekte'. 
Hoofdstuk 2 beschrijft de meta-analyse van drie eerder uitge-
voerde patient-controle onderzoeken naar risicofactoren voor de 
ziekte van Creutzfeldt-Jakob. Voor deze meta-analyse werden de 
ruwe data van de individuele studies, uitgevoerd in de Verenigde 
Staten, Japan en het Verenigd Koninkrijk, verkregen en opnieuw 
geanalyseerd. Ondanks de verschlllen In methodologie nlssen de 
Individuele studies, gebntlkten zlj aile drie de dlagnostische crite-
ria van Masters et aJ. De gezamenJijke dataset bestond ult 178 
patienten en 333 controles. Het rlslco op de zlekte van Creutz-
feldt-Jakob was statistisch Significant verhoogd voor diegenen met 
een positieve familie-anamnese voor de ziekte van Creutzfeldt-
Jakob en voor diegenen met psychose in de voorgeschiedenis. 
Verder was er een - weliswaar nlet significant - verhoogd risko 
voor personen werkzaam in de medische Sector en Vaal' personen 
met blootstelling aan koeien en schapen. De consutnptie van 01'-
gaanvlees was nlet geassocieerd met een verhoogd risico op de 
ziekte van Creutzfeldt-Jakob. De ovelwegend negatieve resultaten 
van de meta-analyse zijn van belang omdat deze de afwezigheid 
bevestigen van een gemeenschappelijke risicofactor voor patien-
ten met de ziekte van Creutzfeldt-Jakob in de periode van 1970 tot 
1984. 
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Hoofdstuk 3 beschrijft in detail de methodologie en de gemeen-
schappelijke opzet van het Europese onderzoek naar de inclden-
tie, risicofactoren en prognose van de ziekte van Creutzfeldt-
Jakob. Allereerst worden de gemeenschappelijke diagnostische 
criteria beschreven. VerdeI' wordt ingegaan op het opzetten van 
de nation ale registers in de palticiperende landen, waar aile 
patienten met de ziekte van Creutzfeldt-Jakob werden aangemeld. 
Met name wordt ultgebreid ingegaan op de ontstaanswijze en het 
fuoctioneren van het register van Nederland en Belgi~. Als laatste 
wordt ingegaan op dataverzamellng, dataverwerking en 
statistische analyse van de drie studies naar incicientie, 
risicofactoren en prognose van de ziekte van Creutzfeldt-Jakob. 
Hoofdstuk 4 geeft de incidentie van de ziekte van Creutzfeldt-
Jakob weer. Van 1993 tot 1995 werden in Europa 570 patienten 
verzameld met een zekere of waarschijnlijke diagnose van Creutz-
feldt-Jakob, reslllterend in een mortaliteitscijfer van 0.73 per mil-
joen persoonjaren. In dit hoofdstuk worden zowel de incidentie-
als de mortallteitscijfers beschreven, die nagenoeg gelijk zijn door 
de gemiddeld korte ziekteduur. De mortaliteitscijfers waren oak 
nagenoeg gelijk voor alle pa!1iciperende landen, ondanks het 
verschil in obductiepercentage. Ook de leeftijdsspecifieke inci-
dentiecijfers vom alle participerende landen zijn nagenoeg gelijk, 
met uitzondering van een sterk verhoogde incldentie van patlen-
ten onder de veertig jaar in het Verenigd Koninki'ijk. Met betrek-
king tot de onderverdeling naar etiologie behoorden 90% van de 
patienten tot de 'sporadische', SOlo tot de 'genetische' en 2% tot de 
'iatrogene' vorm van de ziekte van CreutzfeIdt -Jakob. De inclden-
tiecijfers van de participerende landen zullen als epideilliologi-
sche uitgangswaarden dienen, welke in de toekomst van be lang 
zullen zijn voor het registreren van een mogeHjke verandering In 
het v66rkoillen van de ziekte van Creutzfeldt-Jakob. 
In hoofdstuk 5 worden de resultaten van de geilleenschappelijke 
Europese studie beschreveo naar riskofactoren voor de ziekte van 
Creutzfeldt-Jakob. Vierhonderdenvijf patienten uit de populatie-
studies van de participerende landen werden opgenoluen in het 
patient-controle onderzoek en vergeleken met 405 ziekenhuis-
cootroles. Een statistisch significant verhoogd risko werd gevon-
Samenvatting 
den vaal' patienten met een positieve familie-anamnese voor de 
ziekte van Creutzfeldt -Jakob en voor patienten met eeo positieve 
familie-anamnese voor dementie van andere origine. Verder werd 
een verhoogd risko gevonden VOOl' patienten met blootstel1ing 
aan vagels, kunstmest en produkten van leer. Met betrekking tot 
risicofactoren naar eetgewoonten werd eeo verhoogd risico 
gevonden voor de consumptie van hersenen en rauw vlees. 
Eehter de constlmptie van rundvlees, kalfsvlees, lamsvlees, me1k 
of kaas was niet geassocieerd met een verhoogd risko Vaal' de 
ziekte van Creutzfeldt-Jakob. 
Hoofdstuk 6 beschrijft de studie naar prognostische factoren van 
patienten met de ziekte van Creutzfeldt-Jakob. Zeshonderdenzes 
patienten met de zekere of waarschijnlijke diagnose van Creutz-
feldt-Jakob werden opgenomen in de studie. De mediane ziekte-
duur, gedefinieerd van het moment van eerste symptomen tot de 
dood of 'censoring' danuu op 31 mei 1996, was gemiddeld vier 
maanden. Geslacht, een leeftijd onder de 40 jam en classificatie 
als een waarschijnHjksdiagnose van de ziekte van Creutzfeldt-
Jakob waren belangrijke prognostische factoren. Klinische 
verschijnselen waren niet gerelateerd aan overleving. In 
tegenstelling tot eerdere bevindingen von den wij een verhoogde 
mortaliteit bij patienten met een mutatie van het prion-gen en/of 
een positieve familie-anamnese voor de ziekte van Creutzfeldt-
Jakob. Tevens werd een langere overleving gevonden voor 
patienten zonder mutatie van het prion-gen die drager zijn van ten 
minste cen valine-allel op codon 129. Deze bevindingen tonen 
aan dat er behoudens de nieuwe variant van de ziekte van 
Creutzfeldt-Jakob geen andere klinische subgroep van de ziekte 
van Creutzfeldt -Jakob bestaat die is geassocieerd met overleving. 
Verder benadrukken deze resultaten de 1'01 van genetische 
factoren in de pathofysiologie en prognose van de ziekte van 
Creutzfeldt-Jakob. 
Hoofdstuk 7 geeft in het karl de belangrijkste bevindingen weer 
van de gezamenlijke studies naar incidentie, risicofactoren en 
prognose van de ziekte van Creutzfeldt-Jakob. VerdeI' worden de 
methodologische aspecten van de drie shldies afzonderlijk 
geevalueerd. Tevens worden de implicaties van de bevindingen 
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van de afzonderlijke studies besproken en aanbevelingen gedaan 
voor verder epidemiologisch onderzoek naar de ziekte van 
Creutzfeldt-Jakob. Tot slot wordt nogmaals het belang ulteengezet 
van het continueren van het onderzoek, gezlen de mogeJijk lange 
incubatietijd van het infectieuze agens. 
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